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ABSTRACT 
DO NO HARM: PRESCRIPTION DRUG ABUSE AND THE 
PARAPROFESSIONALISM OF PHARMACISTS 
 
by 
 
Kathrine Barnes 
 
The University of Wisconsin-Milwaukee, 2013 
Under the Supervision of Professor Paul Brodwin 
 
 
 
History reveals long, intertwining chronologies between licit and illicit drugs, and social 
change. Currently, rates of prescription drug abuse are increasing and medical 
professionals at every step must mediate the flow of pharmaceuticals. The effect of the 
epidemic on emerging social change relative to pharmacy remains unexplored. While 
pharmacists are trusted and have shown to be effective in smoking cessation, little 
research has explored the impact of prescription drug abuse on their work. Pharmacists 
have little official authority and autonomy on the job, relegating them to the level of 
paraprofessionals, but pharmacists find novel ways of gaining agency in their day-to-day 
work. In conceptualizing addiction as a patient who lacks awareness and whose mind is 
fragmented by the action of drugs on their body, pharmacists are able to hassle patients 
and attempt to bring awareness of their condition through an assemblage of patient 
records comingled notions of profit, care, biomedicine, a global pharmaceutical market, 
and morality. While relying heavily on physicians to do their work, pharmacists blame 
prescribers for the actions of their patients. In seeing patient’s patterns of use, not the 
effects of the drug, at issue in creating addiction to prescription drugs, pharmacists 
insulate their position of low authority, effectively relegating the problem to doctor’s turf, 
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and absorbing a dialogue of the global pharmaceutical industry while actively 
constructing the effect of prescription narcotics on the addicted body. Through 
pharmacists’ work, those impacted by the prescription drug abuse problem can ascertain 
what happens when the drugs meant to heal the public become profound agents of harm. 
Pharmacists and the rest of the medical community are subordinated by a language and 
conceptualizations rooted in the pharmaceutical industry. 
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Chapter I: Introduction 
 The fallout began in 2006. That year, researchers at the Center for Disease 
Control authored a monumental study showing a significant increase in deaths among 
women who abuse prescription narcotics with a concurrent 500 percent increase in the 
prescribing of such drugs (Paulozzi, Budnitz, Xi 2006). Immediately, representatives of 
the University of Wisconsin Pain & Policy Studies Group, Aaron Gilson and David 
Joranson (2006), refuted these conclusions, cautioning against tightening regulation of 
the drugs: people are in pain; we have a duty to absolve them of pain. Their names litter 
other literature on the dangers of underprescribing—as a citation in a book published by 
the Human Rights Watch entitled Please Do Not Make Us Suffer Anymore: Access to 
Pain Treatment as a Human Right (2009:5), in the Journal of Pain and Symptom 
Management (2002), and in the Indian Journal of Palliative Care (2005). As a 2011 
investigative report by the Milwaukee Journal-Sentinel found, hidden by this record is a 
generous and ongoing financial relationship with several pharmaceutical companies, the 
largest donation of which coming from Purdue Pharma (Fauber 2011a). Between 1999 
and 2010, Purdue Pharma paid the UW Pain & Policy Studies Group over $1.6 million 
according to the Milwaukee Journal-Sentinel. The group’s total pocketed profit from 
pharmaceutical companies exceeds $2.5 million. Purdue Pharma is the producer of 
OxyContin, an expensive, highly addictive narcotic. Users put a pill of Oxycodone onto a 
piece of foil, light it from underneath, and using a straw, inhale the fumes. The following 
year, in 2007, Purdue was brought up on charges by the United States Department of 
Justice for fraudulently misleading prescribers in saying OxyContin was less addictive 
than other pain medications (Meier 2007). The company and three of its executives plead 
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guilty to various charges and over $635 million in fines were imposed on Purdue Pharma. 
Despite this, OxyContin continued to be prescribed at high rates, largely fueled by claims 
furthered by the palliative care movement and the UW Pain & Policy Studies Group. 
Gilson and Joranson had an unexpected path to the organization. While making 
prescribing recommendations to doctors in peer-reviewed journals, neither has an M.D.—
according to the UW Pain & Policy Studies Group website, Gilson has a doctorate of 
social welfare and Joranson, his masters in social work. 
 A year after the UW Pain & Policy Studies Group story broke Daniel Lee had a 
problem. He probably was not aware of the controversy being played out about 90 miles 
away from Milwaukee where he lived and operated as a small time drug dealer. 
Nonetheless, he had customers clamoring for OxyContin. Text messages to his phone 
indicated several of his customers asking for Oxycodone 30s (USDOJ 2013). The 
problem was that Daniel had none. So, Daniel made a decision. He searched on his phone 
for local pharmacies, removed the license plate from his car, and on January 2nd, 2012 
around 1pm, he donned a gray hooded sweatshirt along with a thick black winter coat, a 
knit cap, a scarf, two sets of handcuffs, and a gun and walked into Thompson Serv-U 
Drugs. He walked out shortly thereafter with cash and narcotics (Docter 2012). While 
news outlets reported on the incident, Lee was not immediately apprehended. So, he 
robbed three more pharmacies in a similar fashion over the next two months. In May of 
2012, Lee had a new problem: he was arrested and charged with seven federal felonies. 
He was sentenced to 65 years in prison (USDOJ 2013).  
 While the professional and privileged role of Gilson and Jorenson existed a world 
away from the life of small-time drug dealer Daniel Lee, their experiences are united by 
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the sale and distribution of prescription narcotics. It can be easy to cast these incidents off 
as the acts of three morally misguided individuals; however, their stories merely skim the 
surface of a multi-billion dollar industry in pharmaceuticals. These incidents demand a 
deeper analysis; an analysis to properly contextualize the distribution of prescription 
narcotics. 
 Research is quick to pin the blame on prescribers and the industry as a whole. 
While I do not dispute the legitimacy of these claims, pharmacists are embroiled in this 
conflict in ways both unexpected but illustrative of the wider problem. The proliferation 
of pharmaceutical products throughout society in a variety of licit and illicit contexts is 
indicative as much of liberal prescribing as consumer demand: both spheres are driven by 
deeper conceptualizations of the power of prescriptions to effect change, be it curative, 
therapeutic, or addictive. While doctors are the primary power-holders in the medical 
hierarchy, pharmacists immerse themselves through years of training and on the job 
practice in pharmaceuticals. They represent the link between the liberal prescribers 
targeted by Gilson and Jorenson, and the use of medications in the community, whether 
they are legitimately and “responsibly” taken or bought from the Daniel Lees of the 
streets. Yet, for all the research on prescription drug abuse, the pharmaceutical industry, 
and doctor-patient interactions, research takes for granted pharmacists’ work.   
 Pharmacists’ knowledge deals intimately with the therapeutic effects, side effects, 
and contraindications of pharmaceuticals. By definition, their job is to exchange a 
doctor’s script for the medication itself. Pharmacists are what is termed paraprofessionals, 
professionals without the full trappings of doctors and must rely on prescribers for their 
work (Freidson 1988). The field has undergone an expansion in recent times as pharmacy 
	  	  
4	  
has taken on additional duties, such as administering vaccinations, blood pressure 
consultation, and advising on prescribing in certain hospital settings. Additionally, 
research has shown pharmacists to be highly trusted by the public (Gallup 2013) and 
effective in smoking cessation (Maguire, McElnay, & Drummond 2001). Considering 
their unique positionality with regards to medications, as well as the demonstrated role 
pharmacists can have in patient health, pharmacists’ encounters with prescription drug 
addiction including how they conceptualize drugs and patients are worth documenting. 
 Furthermore, prescription drug abuse warrants a deeper analysis of the literature. 
Epidemiological studies have shown this problem to be unique from the abuse of 
classically illicit drugs. Prescription drug abuse is increasing at both ends of the age 
spectrum, particularly among Caucasians, and is spreading to rural areas (Manubay, 
Muchow, & Sullivan 2011). The abuse of street drugs, in contrast, has generally been 
described as a problem of urban areas and more prevalent among minorities than has 
been observed with prescription drug abuse (Swendsen et al 2012). Additionally, 
prescription drugs of abuse construct a liminal space between the legal, non-abusable 
pharmaceuticals on the market, such as antibiotics, with a clear therapeutic value, and 
entirely illicit street drugs, such as marijuana, heroin, or cocaine. The fact that 
prescription narcotics need to first be acquired with the permission of a doctor and 
dispensed by a licensed pharmacist calls into question the professional roles of these 
actors—how are abusers able to acquire controlled prescriptions for illicit purposes?  
Additionally, prescription drug abuse provides a useful analytic ground in which to 
examine the role of drugs—therapeutic or otherwise—in creating and recreating both the 
self, as a body and addict, and the professional role of pharmacists. 
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 In fact, the juncture of pharmacy and drug abuse is in-and-of-itself not a novel 
analysis—pharmacy and street drugs have shared a relatively long history.  Drugs that 
today are readily categorized as illegal, such as cocaine, were once used to treat illness 
(Acker 2002:2-9). It was only when these substances began to spread into immigrant and 
minority populations that the morality of consuming these substances began to be 
questioned. Quickly, the tide of public opinion began to ebb in the direction of increasing 
legal penalties for the use and illicit sale of such drugs. Demand for substances now 
synonymous with the lower classes waned among upper-class, predominately white 
naturalized citizens and beginning in the early 1900’s, drugs such as marijuana, heroin, 
and cocaine were slowly outlawed. By the time drugs were codified into the Controlled 
Substances Act of 1970 by President Nixon, regulating the prescribing or prohibition of 
all drugs, the pharmaceutical market had become firmly enmeshed into American society. 
Thirty years earlier, in the 1940s, Pfizer developed a large-scale fermentation technique 
able to produce record quantities of penicillin (Williams 1984:124). A decade later in 
1957, the invention of the discreet, female-controlled administration of the birth control 
pill for contraception set the stage for the women’s liberation movement of the 1960s 
(Gordon 2002). While previous forms of birth control were male-controlled, “the pill” put 
birth control firmly and nearly completely in the hands of women and harkening a 
reorientation towards women’s decision-making. The ability of pharmaceuticals to not 
only direct sociocultural change, but generate record profits was clear, most of all to 
pharmaceutical companies now in a feeding frenzy for the drug of the future. The next 
revolution of drug development is generally described as the invention of drugs for 
psychiatric care, namely fluoxetine, or Prozac, by Eli Lilly and Company in 1977 for the 
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treatment of depression, but it was not formally launched until 1988 (Healy 2006). The 
range of drugs marketed to treat psychiatric conditions became a fruitful market for the 
pharmaceutical industry of rather epic proportions, their profits bolstered by increased 
allowance for direct to consumer marketing for pharmaceuticals in 1969 (Ventola 2011). 
As the deinstitutionalization movement of the psychiatric population in the 1960’s and 
1970’s occurred, moving large numbers of the indigent population out of hospitals and 
mental health wards and into the community, these drugs offered a therapy administrable 
in an out-patient setting (Szasz 2007). 
By 1978, Knoll Pharmaceuticals (now Abbott Laboratories) had introduced 
Vicodin, composed of five milligrams hydrocodone and 500 milligrams of 
acetaminophen, or ibuprofen (New York Magazine, 2009). While hydrocodone along 
with opium and morphine is a strictly-regulated Schedule II drug, when mixed with 
acetaminophen, it can be more loosely regulated as a Schedule III drug (United States 
Food and Drug Administration, 1970). While the Controlled Substances Act (1970) does 
not permit Schedule II drugs to be refilled, Schedule III drugs can be refilled up to five 
times in a six-month period. Then, patients have access to four times the drug without the 
inconvenience of having to return to their doctor. Thus, for pharmaceutical companies, 
the looser restrictions on Schedule III drugs equate to more profit. While Vicodin’s patent 
expired in 1983, making the generic version available at a cheaper cost to consumers, a 
variety of other prescription narcotics were patented and sold (New York Magazine, 
2009). In 1995, the FDA approved OxyContin produced by Purdue Pharma as a Schedule 
II drug (FDA, 1995). The product remains under patent as of this writing and not only a 
huge contributor of Purdue’s profits, but a primary drug of abuse. In 2002, sale of these 
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drugs had increased 500 percent since 1990 and by 2006, 130 million prescriptions were 
being written for hydrocodone products (Paulozzi, Budnitz, Xi 2006). In a New York 
Magazine (2009) spotlight on the history of Vicodin, the Director of Pain Medicine at 
NYU, Dr. Chris Gharibo describes the “product loyalty—to physician practice patterns 
that are very Vicodin-based” (2009). Despite concerns regarding the effect of these drugs 
on the liver, Vicodin, hydrocodone, and OxyContin continue to be prescribed for and 
dispensed at record rates, driving rates of the illicit use of these drugs ever higher. 
As this brief history illustrates, illicit as well as licit drugs, sociocultural change, 
pharmacy and the pharmaceutical industry have a long and intertwined story. Drug 
regulation both creates and re-creates social structures—stigmatization of immigrants, 
minorities, and the indigent—and the pervasiveness of these drugs throughout society 
fuel a diverse array of changes from women’s liberation to deinstitutionalization. Even 
today, cocaine, a drug largely associated with upper class white men, although 
chemically similar to crack, a smoke-able form more favored by African American 
populations, carries a lighter legal sentence (Sklansky 1994). African Americans, who 
make up the majority of drug convictions, are more likely both to be arrested and spend 
longer in jail for drug charges than Caucasian criminals. Such racial divides exist in the 
prescribing of prescription narcotics, with doctors prescribing narcotics at significantly 
higher rates to Caucasians than minorities (Pletcher 2008). Despite this, as I witnessed in 
the conduction of my fieldwork, prescription drug abuse is often colloquially viewed as a 
minority drug problem, despite epidemiological trends to the contrary. Drugs, regardless 
of their legal classification, not only constitute an important driving force to sociocultural 
change to which pharmacists are often actors in, but the production, dispensing, and 
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consumption of these drugs constitutes an historically-rooted moral act. Thus, a critical 
analysis of pharmacists, whose work most intimately involves the exchange of scripts and 
money for drugs, offers a useful, but underutilized, ground for exploring questions of 
drugs, the pharmaceutical industry, the self, and the impact of these elements on 
professional roles. 
 To explore these questions and in the midst of the Daniel Lee and UW Pain & 
Policy Studies Group dramas, in February 2012, I began a four-month field project on the 
training and practice of pharmacy in the context of prescription drug abuse. I attended 
several lectures at a school of pharmacy in the upper Midwest and interviewed several 
practicing pharmacists—some newly placed out of school in corporate settings, others 
well established in community pharmacies. Their struggles in combating prescription 
drug abuse both practically and ethically, as well as the training they receive on the 
proper dispensing of medications from antibiotics to OxyContin, reveal a group of 
individuals grappling with a problem that has no easy solution in sight. Their words and 
actions are a testament to the difficulty of attempting to deal with a long-standing, 
ingrained problem from a position of low authority and low autonomy. Pharmacists 
described the multitude of ways they psychologically and practically, always creatively, 
cope with having little on-the-job decision-making.  
 My central thesis is: the conflicts that emerge regarding the (il)licit use of 
prescription drugs allows the professional role of pharmacists and the addicted body to 
become sites where micropolitics between dialogues of medicine and care compete with a 
pharmaceutical industry agenda centered on profit-generating work. Straddled between 
profit and care, pharmacy presents a workable metaphor for the development of medicine 
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and its increasing reliance on the products of the pharmaceutical industry. In how 
pharmacists describe addicts, I will show how their words resonate with the way they 
describe their own work. They describe individuals they suspect as abusing drugs as 
either a “true patient” in need of the medication-as-therapy, or an addict, as individuals 
unaware of their dependence. Nevertheless, as paraprofessionals, pharmacists are often 
forced to dispense to those they believe are addicts with no medical need for prescriptions. 
The resultant futility and ambivalence they feel towards their work and the products of 
this labor is ameliorated in part by blaming physicians who they feel misprescribe 
narcotics in the wrong amounts to the wrong people. Beholden to the idea that drugs are 
good and only one’s use of a medication can be bad, pharmacists rely on an “assemblage” 
of technologies, different iterations of patient records, to legitimize their work, attempt to 
bring awareness of addict’s problems to addicts, and portray their labor as more moral—
i.e., the pharmacists’ drugs are good, but the doctor’s patient is bad. The definition of 
care they produce centered on this dictum reflects a larger theoretical tension surrounding 
pharmaceuticals: what are the pharmaceuticals that both treat disease and cause disease? 
The medicalization of addiction, casting it as a disease state, and “pharmaceuticalization”, 
which perpetuates drugs through society, demand a new definition of therapeutic care and 
of the work dedicated to delivering this care. 
My analysis will begin with a review of the existing literature. As the brief history 
presented earlier introduced the historical derivation for my inquiry, these historical 
precedents will be built upon and contextualized through modern epidemiological studies, 
literature on the sociology of professions, analysis of the pharmaceutical industry—the 
manufacturing of its products as medicinal and social items—as well as framing my 
	  	  
10	  
argument through the lens of Latour’s Actor Network Theory (2005). Next, I hope to 
address how my methods are uniquely situated to answer the questions that I pose. My 
primary data chapters will present support for the arguments introduced above. First, I 
will describe the unique tensions pharmacists feel as paraprofessionals equally situated 
between the worlds of care and profit. I will describe their two ethos centered on these 
worlds and how they collide when dispensing drug of abuse for profit to addicts whom 
they believe are harmed, not helped, by prescription narcotics. By conceptualizing addicts 
as unique from patients, pharmacists construct a new ground upon which to antagonize 
addicts and attempt to keep the medications from going into their hands. Yet, as rising 
prescription drug abuse rates attest to, their efforts often fail their objectives. For this, 
pharmacists place a great deal of blame on prescribers. Such blame serves both to set the 
boundaries of their profession, centered upon the medications, as distinct from 
prescriber’s realm concerned with patient diagnoses and treatment outcomes. Yet, their 
reliance on doctors to write scripts that predicate pharmacist’s labor creates an overall 
feeling of ambivalence on the part of pharmacists towards prescribers. Their small acts of 
defiance, blame, and patient hassling allows pharmacists the liberty granted them by their 
paraprofessional role; by readily working from such a constrained position, they avoid 
shouldering the blame for the problem their labor creates. Thus, their ambivalence 
legitimates their position as dependent upon, but unique from, prescribers. To further 
combat the futility of dispensing to those they suspect have no “legitimate” demand for 
the medication, pharmacists produce a collection of patient records, the only tangible 
product of their suspicions. These records are available to other locations within a 
corporate chain, or possibly to doctors, police officers, and others through Prescription 
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Drug Monitoring Programs (PDMPs). These records compose an assemblage, meant to 
bring awareness of the drugs’ effects to addicts. A specific definition of care emerges. 
While decidedly centered on pharmaceuticals, pharmacists continually grapple with the 
juxtaposition of their training, which proffers pharmaceuticals as panaceas to any array of 
ills, with the reality that some of these pharmaceuticals produce an ill themselves, that is 
prescription drug abuse.  
Ultimately, this tension is not unique to pharmacy, but representative of all 
domains of medicine. In a medicalized society that creates diagnoses for an increasing 
number of human states in an era of pharmaceuticalization that produces a never-ending 
stream of medicines to treat these ills, the bodies constructed through these processes of 
care, as well as the nature of care itself is radically transformed. Any answer to the 
prescription drug abuse epidemic will have to address these fundamental questions. 
Meanwhile, the hegemony of the pharmaceutical industry renders the medical community 
conceptually ill equipped, operating from a similarly constrained and futile position, to 
attempt to hedge the burgeoning abuse epidemic. 
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Chapter II: Literature Review 
 The supremacy with which physicians are afforded within the context of the 
medical field is intuitively known, so as to be nearly an a priori assumption. Researchers 
have adopted this stance as well, elucidating several nuances to doctor-patient and 
doctor-pharmacist interactions into a long history on the subject of doctors’ role in 
delivering healthcare. The fact that physicians have a higher degree of professional 
autonomy in their jobs relative to other healthcare professionals, such as pharmacists, 
warrants this line of inquiry. Within the prescription drug abuse literature in anthropology, 
which is scant, doctor’s authority and autonomy on the job provide the most obvious 
research interest, as they are the first gatekeeper (for lack of a better word) abusers 
encounter in gaining possession of prescriptions to abuse. Most research on prescription 
drug abuse seems predicated on the notion that altering doctors’ decision making offers 
the best site of intervention to eradicate or at least slow down or understand the 
increasing rates of prescription drug abuse.  
However, as I will argue herein, pharmacists who experience work characterized 
by multiple professional constraints offer another profitable site of inquiry. Not only are 
pharmacists the only healthcare professionals who handle the medications people abuse, 
but pharmacists also exist on the interstice between profit generating business and the 
realm of healthcare concerned with patient care. I proffer the reorientation of drug abuse 
and addiction literature to accommodate what I identify as the unique set of 
circumstances surrounding the acquisition of prescriptions for illicit use (in contrast to 
classically illicit drugs of abuse), the role of cultural notions of drugs, the body, and 
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cognitive experience, as well as the professional role of pharmacists can lend to an 
understanding of drugs, society, and professionalization in general. 
Epidemiology. Prescription drug abuse is defined as the use of drugs targeting the 
central nervous system taken for nonmedical purposes. While rates of prescription drug 
innovation measured by spending and the emergence of new medications has declined 
since 2007 (Aitken, Berndt, & Cutler, 2009), rates of prescription drug abuse escalated 
during this time (NIDA, 2011) meaning increasing rates of prescription drug abuse are 
not driven by an increase in the number of abusable drugs available. 7 million 
adolescents reported abusing pharmaceuticals and 5.1 million of these cases involved 
painkillers. In fact, the use of prescription drugs such as Vicodin and Adderall are 
eclipsed only by marijuana. According to NIDA (2011), the rate of increase for 
prescription pill abuse (94 percent) between 1992-2003 exceeded the rate of increase for 
any other drug. Meanwhile, between 1991-2010, prescriptions for stimulants increased 9-
fold (5 million to 45 million) and prescriptions for opioid analgesics increased 6-fold (30 
million to180 million). Specifically, pain relievers such as Vicodin and OxyContin 
constitute the pills of choice for most abusers. The use of oxycodone HCl with at least 
one other opioid was reported by 92 percent of users. Abuse is increasing at both ends of 
the age spectrum—young adults and those aged 65 or older report increasing use of non-
medical prescription use between 2002-2007 (Pletcher 2008). Such users are 8 times 
more likely to concurrently abuse tranquilizers and 5 times more likely to concurrently 
abuse prescription opiates (Aitken, Berndt, & Culter, 2009). In contrast, rates of polydrug 
abuse in abusers of classically illicit drugs are comparatively lower, particularly when 
marijuana and alcohol are not considered, as these drugs have universally high rates of 
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abuse across most demographics. Additionally, classically illicit drug abuse is 
overwhelmingly limited to adolescents and young adults (Compton et al, 2005). Thus, the 
epidemiology of prescription drug abuse differs significantly from the abuse of 
classically illicit drugs.  
Furthermore, prescription drug abuse is unique from other forms of drug abuse in 
that Caucasians use at a higher rate than Hispanics or African Americans across all 
classifications of prescription drugs—stimulants, anxiolytics, and opioid analgesics (Ford 
& Rivera, 2008; Gunter et al., 2012; Kroutil et al., 2006; McCabe, 2005; McCabe et al., 
2006; Simoni-Wastila & Strickler, 2004; Sung et al.; 2005). Additionally, conflicting 
reports exist as to whether education is a protective factor in prescription drug abuse as 
with use of other drugs (Gunter et al., 2012; Harrell & Broman, 2009; Huang et al., 2006; 
Merline et al., 2004).  
Nonmedical use of prescription drugs also differs from abuse of classically illicit 
drugs in that individuals are often introduced to prescription drugs through legal channels 
as a result of organic maladies. When an individual develops tolerance and withdrawal, 
the hallmarks of addiction, as the result of the legal use of a medication to treat a 
medically diagnosed illness, what is termed “iatrogenic addiction” (Musto 1984). While 
it is not currently known how many individuals currently abusing prescription 
medications began in iatrogenic addiction, the number is potentially as high as the abuse 
rate of opioids, the most abused class of prescription drugs. Opioids also constitute one of 
the most prescribed classes of drugs on the market. Studies cataloguing the prescribing 
rates of opioids have found physicians are more likely to prescribe opioid analgesics to 
Caucasians. Additionally, the rate opioid analgesics are prescribed has increased with 
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rates of abuse of these drugs (Pletcher et al., 2008). While this association does not 
necessarily indicate causality, the correlating trends that suggest iatrogenic addiction are 
intriguing. These data add another dimension to prescription drug abuse not seen in other 
forms of abuse—that is, the potential that addicts previously, currently, or at some point 
in the future may have a medical need for medications with an abuse potential. The fact 
that drugs such as Adderall, Vicodin, or Valium shift between legality and illegality 
complicate the study of prescription drug abuse. 
Different demographics in prescription drug abuse compared to classically illicit 
drugs and the different pharmacology of prescription drugs leads to new problems in 
combating the problem. Approximately 60 percent of those taking prescription drugs for 
non-medical purposes obtained the medications from a friend or family member (Aitken, 
Berndt, & Cutler, 2009). According to NIDA (2010), those friends or relatives largely 
report receiving the prescriptions for these medicines from only one doctor (81.7 percent). 
Acquisition from street dealers (4.3 percent) or the internet (0.4 percent) constitutes a 
small fraction of the pills abusers take. The issues arising from this fact are twofold. On 
one hand, current literature predominately discusses preventing prescription drug abuse 
through education to providers about the “warning signs” of addicts. However, this 
statistic indicates that prescribers are often not coming into contact with the abusers 
themselves. A knowledge gap exists in how information into how prescription drug 
abusers acquire drugs and conceptualize their use could inform prevention aimed at 
prescribers or pharmacists. Secondly, this statistic indicates that the acquisition of 
prescription drugs occurs through channels unmediated by formal control. Whether 
friends or family members knowingly provide drugs to abusers or if abusers steal the 
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medications without the knowledge and consent of those the medications are prescribed 
to is not known. Additionally, unlike illicit drugs acquired through drug dealers who are 
likely more or less strangers, exchanges of prescription drugs are occurring through 
established personal relationships. The different ways prescription drugs are acquired and 
motivations for the use of these drugs relative to classically illicit drugs in light of 
increasing rates in both older and younger Americans demands new ways of 
conceptualizing prescription drug abuse.  
Thus, prescription drug abuse differs epidemiologically from the abuse of street 
drugs namely in the emergence of abuse of such drugs amongst Caucasians, across the 
age spectrum, and through legal and legitimate prescribing of drugs of abuse otherwise 
known as iatrogenic addiction. Opioid abuse constitutes the classification of drugs largely 
considered of most concern due to users switching to heroin when access to prescription 
opiates wanes (Wisconsin Department of Justice 2013). Heroin abuse, although similar in 
chemistry and effects to prescribed opiates, introduces concomitant risk of HIV/AIDS or 
hepatitis C transmission through the use of hypodermic needles along with increased risk 
of death from overdose as street heroin can vary greatly in potency. 
Prescription Drug Monitoring Programs (PDMPs). These data have contributed 
to a swell of public attention both inside and outside the academic sphere towards 
prescription drug abuse. Research is only beginning to expand beyond description 
epidemiological work, including evaluations of prescription drug monitoring programs 
(PDMPs). Sometimes simply referred to as Prescription Monitoring Programs (PMPs), 
such programs track medications dispensed to patients across the state. Federal justice 
programs and the U.S. Department of Justice offer grants for states to implement PDMPs 
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in their states. Currently, 37 states have implemented a statewide monitoring program, 
and 11 states along with the U.S. territory of Guam have enacted legislation to establish 
PDMPs, but are not fully operational as of October 2011 according to the The Alliance of 
States with Prescription Monitoring Programs (ctd. in USDOJ 2011), which advises and 
informally oversees the implementation of such programs. A total of 48 states have 
operational or nearly operational PDMPs. Wisconsin, where the present study was 
conducted, during the duration of data collection did not have a functioning PDMP, but 
was one of the 11 states with legislation in place to support the formation of one.  
Despite the success the organization has had in proliferating PDMPs across states, 
their implementation has received significant criticism. A recent article in the Journal of 
the American Medical Association asks, “Can Prescription Drug Monitoring Programs 
Help Limit Opioid Abuse?” Authors Gugelmann and Perrone note the lack of uniformity 
in the implementation and design of PDMPs as a major obstacle to their effectiveness in 
curbing opiate abuse trends. Some programs are available to clinicians, while others are 
limited to law enforcement. Some states enable real-time updates after a prescription is 
dispensed, while other programs update only periodically. Additionally, limited 
communication between states’ PDMPs do not protect against patients who may cross 
state boundaries to acquire prescriptions, which is of particular importance to 
Northeastern states and areas or cities located close to state borders such as Milwaukee 
and Northeastern Wisconsin. 
 Professionalization of Pharmacy. The field of pharmacy offers a productive site 
for generating new conceptualizations of prescription drugs. Research to date has 
predominately been focused on prescribers likely because physicians have greater 
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authority and professional autonomy in writing prescriptions relative to other medical 
professionals. However, research investigating the role of pharmacists in smoking 
cessation has long proven these paraprofessionals can be effective producers of change in 
the public’s consumption patterns of addictive substances (Zillich, et al. 2012). In 
addition, pharmacists expansive training in pharmaceuticals both in the academic and 
praxis spheres makes them important conduits for the cultural significance and roles of 
such medications. Given the unique epidemiology of prescription drug abuse, knowledge 
of the deeper significance of pharmaceuticals in society may bear on the nature of this 
problem and perhaps few professionals are involved so wholly in the medications 
dispensed to the public than pharmacists. Thus, the notion that a study of pharmacy to 
uncover the significance of drugs and addiction in society is rooted in prior research and 
while it reasons pharmacists may be capable to positively impact the quickly increasing 
trends of pharmaceutical abuse, no studies to date have analyzed how pharmacists’ 
operate under new constraints imposed by prescription drug abuse. 
 Pharmacists have become increasingly important, as the repertoire of drugs on the 
market has expanded exponentially over the course of the modern age. Accordingly, 
pharmacists have been subject to an expansion in training from a four-year degree to a 
six-year PharmD degree (American Association of Colleges of Pharmacy 2013). Despite 
these new requirements, the number of accredited pharmacy schools swelled from 72 in 
1987 to 128 in 2012 (Brown 2013). While new practice settings emerge for pharmacists 
working alongside doctors to develop pharmacotherapeutic treatment regimens, research 
showing pharmacists’ effectiveness in smoking cessation is encouraging for the 
professionalization of an oft-forgotten discipline (Zillich, et al. 2012). Furthermore, 
	  	  
19	  
according to Gallup polls dating back to 1981, pharmacists are consistently ranked the 
most or second most trusted professional and their rates of trustworthiness have steadily 
increased since the poll’s inception; the percent of the public saying their trust in 
pharmacists is “high/very high” currently sits at 75 percent, second only to nurses with 85 
percent and a healthy 5 percent above medical doctors (Gallup, 2012). Altogether, these 
data paint a promising picture for the capacity of pharmacists to positively impact 
healthcare.  
 The lack of attention paid to pharmacists in the literature is not surprising given 
their lower status as paraprofessionals relative to physicians. Eliot Freidson is perhaps the 
most well known chronicler of the sociology of health professions. In his seminal work, 
Profession of Medicine (1974), Freidson lays out the characteristics imputed to 
professionals including, “a formal standard curriculum of training, hopefully at a 
university. They create or find abstract theory to teach recruits. They write codes of ethics. 
They are prone to seek support for licensing or registration so as to be able to exercise 
some control over who is allowed to do their work” (76). While paraprofessionals, 
including pharmacists, may obtain all the trappings of full professionalization, as 
Freidson notes the defining factor of professionals is autonomy. Freidson states, “while it 
is legitimate for [paraprofessionals] to take orders from and be evaluated by physicians, it 
is not legitimate for them to give orders and to evaluate physicians. Without such 
reciprocity we can hardly consider them the equals of physicians” (76).  It is, however, 
difficult to imagine individuals, particularly trained in a field, complicit in or entirely 
limited by this subordination. My research further illumines the ways in which 
pharmacists as paraprofessionals find agency in their role marked by low professional 
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autonomy. Specifically, I hope to further build on Freidson’s exploration of the 
boundaries and qualities of paraprofessionals vis-à-vis prescription drug abuse. 
 Addiction and abuse: Connotations and history. The term “addict” emerged in the 
sixteenth century from the Latin words addictus, as the past participle of addicere 
(dicere= to say; to adjudge or allot; assigned by decree; Oxford English Dictionary 2013). 
Although now long defunct, this interpretation of the word survives in the colloquial way 
in which the word “addict” is moralizing and often socially prescribed. Awareness of the 
pejorative use of the term led professional organizations such as the American Psychiatric 
Association who composes the Diagnostic and Statistical Manual currently in its fifth 
iteration, to use the diagnostic term “substance dependence” (2013). Nonetheless, the 
phrase “substance dependence” preserves certain connotations of the word “addiction” in 
how denial is frequently utilized to describe this state, i.e., substance abuse and addiction 
are rarely self-assigned descriptors, rather they are assigned by friends, family or the 
public at large and an individual’s protestations and failure to absorb the term are recast 
as denial.  
 Today, substance dependence in its many iterations is characterized as a disease 
state. However, this notion dates back to 1878 with the invention of the hypodermic 
needle making a form of opium and precursor to heroin prevalent at the time an injectable 
and potent medicinal (Parssinen & Kerner 1980). Concerns about new trends in the 
behavior of those prescribed the treatment culminated in a full disease model of addiction 
in 1910. The fact that increasingly the drug was spreading out of the formal, mainstream, 
medical sector and becoming comingled with other illegal and immoral behavior of the 
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time, the fringes of society, as well as to minorities and immigrants hastened a new era of 
drug policy and regulation (Acker 2002:2-9). 
 As suggested already, medicinals and illicit drugs have long shared a fluid and 
constantly shifting boundary. Heroin, cocaine, and amphetamines were once used to treat 
an array of health complaints, but are now strictly relegated to the black market. As the 
pharmaceutical industry gained traction in the world market and the emergence of new 
drugs quickened continually since the 1950’s, it is hardly surprising the number of legally 
prescribed medications with an abuse potential continued to rise. The rate of prescription 
drug abuse first was reported on by the popular Monitoring the Future prevalence study 
administered by the NIDA in 2002. Since then, reported rates of Vicodin abuse have 
steadily increased from 2.5 percent to nearly 3 percent (2012). Although not initially 
impressive, declining rates of other illicit drugs suggest prescription drug abuse is 
increasing, while steadying national averages of all illicit drug use. Increasingly, 
individuals with problematic use of Vicodin or OxyContin are being introduced to a new 
line of pharmacotherapeutic treatments in the form of buprenorphine, naloxone, 
Suboxone (which combines the two), or Vivitrol. Such treatments have slightly different 
mechanisms of action but are promoted for their ability to supposedly decrease craving 
and/or inhibit the effect of opiates on the central nervous system. Criticisms abound 
regarding the safety of such medications and the irony of treating prescription drug abuse 
with prescription drugs of questionable safety and efficacy is not lost on a variety of 
researchers and practitioners (Bazazi 2011, Gwin Mitchell et al. 2009, Meyers, 2013). 
 Addiction-as-disease is understood by two main processes: tolerance and 
withdrawal (American Psychiatric Association 2013). Tolerance refers to an individual 
	  	  
22	  
needing more of the drug to achieve the same effect; while, withdrawal is the presence of 
adverse symptoms at the discontinuation of the drug. A proliferation of articles of the 
biomedical perspective explore the neurochemical and neurological mechanisms of these 
processes, but also serve to legitimize the diagnosis and the professionals that dispense 
these labels and the medications that both cause and presumptively treat this affliction. 
What is not captured in this simple yet complex, modern yet archaic concept of addiction 
is how such shifting definitions of what is and is not addicting impact the professional 
lives of those entrusted with the health and care of the public, particularly as the divide 
between legal and illicit drugs vis-à-vis prescription drug abuse ever blurs these 
boundaries. 
 Medicalization and pharmaceuticalization. Medicalization is widely researched 
phenomenon describing the process whereby human conditions become treated as 
medical conditions. Within the context of the history of addiction, medicalization is most 
obvious in the shift from addiction as a personal moral failing and the emergence of the 
disease model of addiction.  The move has fueled a variety of medically-oriented 
treatment regimens, both psychotherapeutic as well as medicinal. Twelve-step programs, 
for instance, heavily rely on the notion of addiction as a disease. In the group reading 
entitled “Why Are We Here?” read at the beginning of each NA meeting, the 
organization explicitly states their stance on the status of addiction as a disease. “After 
coming to NA, we realized we were sick people. We suffered from a disease from which 
there is no known cure” (1986). Those intimately involved with addiction recovery 
adhere strictly to this thinking as it removes much of the blame inherent in the idea 
medicalization replaced—addiction as willfull deviancy resulting from deep, personal 
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failings. Although stigma predicated on this thinking continues in the collective 
consciousness as supported by decades of the “War on Drugs” and increasing minimum 
sentences for drug crimes, medicalization has nevertheless been a powerful counterforce.  
 While detractors of medicalization note its overuse (Kleinman in Bell & Figert, 
2012), the concept of pharmaceuticalization, a related but distinct term, have emerged to 
describe the treatment of an aspect of the human condition by pharmacological agents 
(Bell and Figert 2012:776). The paradigm is useful in analyzing both the proliferation of 
treatments such as Suboxone to treat addiction to Vicodin or other prescription opiates, as 
well as the growth of the illicit market for prescription opiates for abuse. Complimentary 
to pharmaceuticalization from the perspective of consumers, is its effect on the move of 
pharmaceuticals from the prescriber to the pharmacy and into the increasingly eager 
hands of the public. Additionally, how the phenomenon actively shapes the definition of 
addiction within formal, professional spheres and influences decision-making among the 
only professionals to physically handle pharmaceuticals is a gap in the literature the 
current study hopes to address, at least in part. 
Theoretical framework. Since legal actions, such as those taken against 
GlaxoSmithKline in New York by then Attorney General Eliot Spitzer in the spring of 
2004 (People of the State of New York v. GlaxoSmithKline 2001), and the Vioxx 
controversy wherein Merck voluntarily withdrew the osteoarthritis drug from the market 
after evidence showed it significantly increased heart disease and stroke, increased public 
and academic attention has been paid to medical ethics as they pertain to the 
pharmaceutical industry. Several authors and researchers have uncovered the abuses of 
the medical industry by pharmaceutical companies.  
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One such work by Howard Brody (2007), professor and director at the Institute 
for the Medical Humanities at the University of Texas Medical Branch at Galveston, 
describes how medicine is “hooked” on the pharmaceutical industry in two ways. He says, 
“in one sense, medicine’s relation to the pharmaceutical industry, and the gifts and 
rewards that it dispenses, has been likened to an addiction. Addiction has been called the 
“disease of denial,” and we will see that denial characterizes many aspects of medicine’s 
assessment of this relationship” (5). Brody’s book gives a thorough analysis of 
medicine’s betrayal of public trust for the money and funding provided by 
pharmaceutical companies. Brody’s work focuses on what he calls the “industry-
profession interface,” or the relation of the pharmaceutical industry to the physicians who 
often receive funds to garner research aligned with the pharmaceutical industry’s goals 
and prescribe these medications and the Food and Drug Administration (FDA) who is 
charged with regulating prescriptions. However, Brody explicitly shies away from 
speaking to the industry’s relation to society at large, or drawing specific parallels 
between the way addiction is characterized on an individual level to the medical system’s 
relation to drugs: namely, what logic predicates the role of such denial in addiction? The 
emergence of prescription medications away from therapeutic agents and towards drugs 
of addiction makes this question of particular import to studies of addiction, as well as the 
medical industry. Lastly, Brody’s work and other work critical of the pharmaceutical 
industry’s role in medicine makes it possible to ask: what parallels may exist between 
individual-level addiction and the flow of medications out of the pharmacy and into the 
public’s hands in a lived, real-world context?  
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 From an economic perspective, Kalman Applbaum (2010) explores the 
perception of the side effects of Zyprexa in the drug’s expansion to the Japanese market. 
He describes the “shadow science” used to downplay and recast the harmful side effects 
of the drug and manipulate prescriber’s interpretation of these effects to facilitate such 
expansion. Applbaum makes clear how pharmaceutical marketing influences prescribers; 
however, an interesting question that arises from his work is: how expansive is this 
influence? Is it possible those that rarely come in direct contact with pharmaceutical 
company marketing and have limited decision-making power have similarly been 
subsumed by the a “shadow culture” that insists on casting pharmaceuticals as universal 
forces of health? Michael Oldani (2004) similarly analyzes the implications of the 
pharmaceutical market from a global-economic perspective, but combines his analysis 
with a personal-psychological interpretation. He notes, “pharmaceutical companies are 
quick to promote to doctors (and to the general public) that the patient’s best interest is 
always being served with the introduction of new medications” (338). Again, 
pharmaceuticals are pushed as unqualified agents of health, in this case, explicitly to 
prescribers and the public at large. While ostensibly extolling the value of 
pharmaceuticals with the patient’s health in mind, the discourse of pharmaceutical 
marketing both on an international and interpersonal scale actually serves to further a an 
inherent logic to meet the industry’s (versus the patient’s) needs. As Applbaum notes on 
the global distribution of pharmaceuticals, the reason for which he gives as “because their 
output is held to be the fruit of medical and pharmaceutical science, which operate on 
universal principles and whose importance is acknowledged everywhere. The global 
distribution of medicines carries the legitimating force both of science and ethics, insofar 
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as the speedy delivery of drugs to the sick is an unquestioned good. Good medicines 
should ‘sell themselves’ insofar as their utility need not be argued” (236). The same logic 
predicates the distribution of medicines in an interpersonal relationship, as between a 
doctor and patient, or pharmacist and patient, as the sphere of the global and local 
contexts of pharmaceuticals are difficult and possibly lack utility in being disentangled. 
At another end of the chain from pharmaceuticals to consumption, Paul Brodwin 
(2010) analyzes front-line clinicians in community psychiatry who must actively 
negotiate compliance to pharmaceuticals with patients at the edges of society. Brodwin 
describes the “assemblage of compliance” composed of the competing interests of case 
managers and patients as mediated through an array of physical artifacts of great 
theoretical and practical import, including the container that separates patients daily 
medication allotments (termed a “med cassette”), paperwork, medical supplies, and 
treatment order. Compliance is then cast as micropolitics between the constrained 
position of both the caseworker bound by policy and law, and patients bound by their 
own low social status and as recipients of care. Taken together, Brodwin, Applbaum, and 
Oldani share a common theoretical root in Bruno Latour’s Actor-Network Theory (2005). 
Be it data on the side effects of a pharmaceutical product, a “gift exchange” that 
facilitates a multi-billion dollar global economy through personal exchanges, or a “med 
cassette” exchanged between a case worker and patient, the threads connecting and 
interweaving all the components of how medications are produced, sold, exchanged, and 
consumed often between two highly constrained positionalities actively construct a 
dialogue regarding the role of drugs in society.  
	  	  
27	  
To this dialogue, I hope to add a voice often so lost in the milieu it frequently 
goes unnoticed and arguably taken for granted—the participatory role of those that 
dispense a pill at the injunction of a doctor’s prescription pad. Pharmacists constitute a 
key role in the exchange of pharmaceuticals from their production and sale as part of a 
corporate structure, mediated through company representatives to prescribers, from those 
that have the authority to grant permission for patients to access these products, to the 
actual consumption of such medication by patients. Pharmacists also represent one of the 
most accessible components in the system. Frequently located outside clinics or hospitals, 
in hubs of business and economic activity within the community itself through 
employment in corporate pharmacies, pharmacists take no appointments and sometimes 
work third shifts in 24-hour pharmacies while other medical establishments are closed. 
While pharmacists swell in numbers (a 60 percent increase since 2000 according to 
Brown, 2013), are generally are not targeted by pharmaceutical company reps, and have 
little autonomous decision-making power, it is curious to ask: have pharmacists absorbed 
the dialogue that characterizes the wider exchange of pharmaceuticals? What would this 
dialogue and these negotiations and micropolitics as lived in a real-world, daily practice 
look like? These questions grow ever more pertinent as prescription drug abuse rates 
continue to soar, continuing to blur the line between licit and illicit and call into question 
the use and role of certain classes of abusable pharmaceuticals. Furthermore, prescription 
drug abuse becomes a site in which the patient-care centered dialogue of medicalization, 
which ultimately seeks to provide care for whatever comes to be defined as an ill, collides 
with the pervasiveness of pharmaceuticalization, a trend characterized by the profit-
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generating work of multinational corporations whose products increasingly define 
medical care across the globe.  
Conclusion. Prescription drug abuse constitutes a problem of growing concern for 
medical professionals and communities. The abuse of pharmaceuticals for non-medical 
purposes shares similarities with, but sharply diverges from the abuse of classically illicit 
drugs. While measures such as prescription drug monitoring programs (PDMPs) seek to 
more clearly define the boundary between licit and illicit use, a history of social theory 
predicates inquiry into the role of similar technologies, including the medicines 
themselves, as Latourian artifacts. Historical precedents establish “addiction” and its 
descendent term “substance dependence” as social designations and constructions as 
much as diagnoses. Pharmacists represent a under-researched but potentially fruitful site 
of inquiry into how a descriptor such as “addict” become encapsulated in a medicalized 
and pharmaceuticalized discourse, how these terms are absorbed by the fringes of 
medical society, as well as the iterative process by which these new but familiar 
micropolitics shape the paraprofessional role of pharmacists. 
The way in which those medical professionals that deal most directly with the 
medications themselves in the script-for-pills exchange absorb the logic of 
pharmaceutical marketing has great import for the evolution of pharmacy as a profession, 
the prescription drug abuse epidemic, and wider sociological thought on the role of drugs 
in society. The logic underpinning the work of pharmaceutical corporations, prescribers, 
caregivers, and the healthcare system is becoming increasingly entangled as care 
becomes directly synonymous with medication. The consequences of these developments 
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and thinking, while buttressed by existing literature, are currently unanswered, yet 
constitute a useful and extremely pertinent investigation. 
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Chapter III:Methods 
 Anthropology is a science unique from other disciplines in that meaning is 
interpreted from human experience and the a priori assumption that an absolute truth 
exists is abandoned in favor of personal, relative truths. Clifford Geertz’ famous quote 
proves quite apropos decades after its composition that “man is an animal suspended in 
webs of significance he himself has spun, I take culture to be those webs, and the analysis 
of it to be therefore not an experimental science in search of law but an interpretive one 
in search of meaning” (1973: 5). As an undergraduate student in anthropology and 
psychology, I did not fully appreciate the wisdom and perspective of this quote until I 
undertook my first truly anthropological research assignment my first semester in 
graduate school. While immersing myself through participant observation of Narcotics 
Anonymous groups and interviews with recovering addicts, I was able to fully embrace 
the utility of an interpretive approach to meaning. While biomedicine strictly adheres to 
the idea of addiction as a biological disease, I discovered those who struggled with 
addiction found strength and power in their personal psychological victories in 
overcoming substance abuse. While literature on addiction readily casts addicts as 
victims of a drug’s power over their thinking and behaviour, in fact, the recovering 
addicts I came to know as a result of the project relayed their agency in both their drug 
use and recovery.  
I remember quite clearly meeting with one interviewee and my experience 
cemented these personal views. I had known this individual for a few months and was 
grateful he had agreed to meet with me. We met to conduct the interview and before I 
could formally begin, he said he had some questions for me. He wanted to know my 
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opinions on addiction and Narcotics Anonymous as a recovery program. I explained to 
him I was not concerned with deciding whether NA was effective, but, accepting its 
efficacy, why it was effective from the perspective of those who had found success in the 
program. He was further comforted by my admission that while I was “the researcher”, I 
privileged his knowledge and experience with addiction and recovery over the 
professional literature; I was hoping he could educate me about his experience, not match 
the legitimacy of his words to the objective truths extant in the literature. He was candid 
in his interview and his candor throughout gleaned some of the most useful data for the 
project. I came to understand that allowing the voice of those with native knowledge of 
addiction to be heard in the “Ivory Tower” of professional literature was both an ethical 
and methodological imperative. 
 Anthropology is unique from other disciplines in yet another way. The 
positionality of the researcher as both a producer and reproducer of data comprises a 
central way anthropology recognizes and embraces bias, instead of attempting to reduce 
it in the pursuit of objective truth as is the case with positivistic science. Renato 
Rosaldo’s admission that his understanding of headhunting among the Ilongot was 
limited before the grief brought on by his own wife’s death allowed him to connect with 
the practice more deeply is a widely familiar example of this practice (1980). Similarly, 
my positionality growing up with prescription drug abuse has informed my research and 
perspectives and my story has intimately directed the undertaking of my research. One of 
the most poignant memories of my childhood was finding my father’s cache of 
prescription bottles and baggies of white powder under his bed. I was confused at the 
time why several of them were not in his name, but the memory stuck with me and as I 
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witnessed friends begin using drugs, I came to understand why my father would fall 
asleep at odd times of day juxtaposed with extreme bouts of energy. I became estranged 
from my father early in my adolescence as he slowly slipped out of my life. In first 
undertaking this research, I felt a profound connection with a side of his life that always 
remained remote from me.  
After completing my fieldwork and in the midst of writing my research, I was 
informed of my father’s death from a heart attack. Like Rosaldo, my struggles with 
experiencing the grief of my father’s loss made my subject alternatively cathartic and 
emotionally raw and deepened my experience with the subject of prescription drug abuse 
and addiction. Although I spoke with and observed pharmacists, I was grateful for their 
constant sensitivity to patients who struggled with abuse. They did not see their labor as 
separate or even parallel from the experience of addicts themselves and it was important 
for me personally and for the integrity of my analysis to translate this same holistic 
perspective to my labor. While researching drug abuse history and modern trends, I 
undertook the personal project of researching my father’s life and the years of life I had 
not been privy to. I was able to learn he kept the history of his use a secret from his 
family. I have similarly struggled with how to express being the daughter of a drug 
abuser—the fear of the halo of his drug abuse encompassing me and others’ perception of 
me, my similar unwillingness to be seen in the light of the substances whose power and 
voice seem to echo louder than the people who use them. Thus, the stigmatization of drug 
abuse and the power of substances through their social construction to connect and tear 
apart familial and professional structures was not an experience-far topic, but rather a 
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process I was actively swept up in along with the pharmacists whose lifework had been 
similarly altered in response to prescription drug abuse. 
 I suspect for these reasons, my analysis differs from other research on the topic. 
The aspects of the problem my personal encounters illumined and alternatively, the 
nuances my biases left me blind to color my perspective in ways I anticipate and in other 
ways I cannot. Far from a limitation, I prefer to view this analysis and the problem of 
prescription drug abuse itself as a human construction, as living and evolving as those 
that shape the nature of this problem everyday. My primary aim as both a person affected 
by and researcher of addiction is to allow the evolution of this problem, the policies and 
countermeasures adopted, to be directed by the real-world lived experiences of all the 
actors involved through the research I view as most ethical and most sound. Thus, 
contributing the experience of pharmacists with regards to this problem became an 
essential undertaking. As can be expected, the ways I describe my personal experience as 
intertwining with my research subject is far from complete. 
 My four-month excursion in the field began in early 2012. Preliminary research 
into the literature on prescription drug abuse produced limited gains, as the body of 
literature then much as now is largely relegated to epidemiological description. My 
search for literature analyzing the profession of pharmacy produced an equally narrow 
range of literature. Thus, I decided to begin my experience the same way pharmacists do, 
in a pharmacy education program. I attended lectures and labs at a pharmacy school in 
the upper Midwest for approximately three months. I was immediately shocked by the 
difficulty in engaging a bureaucracy for fieldwork in comparison to an organization such 
as Narcotics Anonymous. Unfamiliar with the methods of anthropological research, 
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department heads were immediately suspicious of my presence. Despite my entreaties 
that my intentions were legitimate and going through the proper channels of Institutional 
Review Board Approvals for both my institution and theirs, they quickly limited my 
access. My initial entrée into the institution via a faculty member proved a constraint, as 
my observation took place in a different department. I became aware a professional 
competition existed between the faculty member I initially made contact with and the 
department chair in whose department I ended up conducting research. In no uncertain 
terms, the constraints of my fieldwork were tightened. I was strictly disallowed from 
communicating at all with students, but was allowed to attend lectures, audio record them, 
and attend labs under the supervision of another faculty member.  
 While I had originally intended to conduct interviews with students, this option 
was quickly tabled and I sought interviews with current practicing pharmacists. Through 
mutual friends, I connected with a number of pharmacists ranging in level of experience, 
setting, and background, including pharmacy students of a third institution. The 
experiences they shared constitute the majority of the data presented herein. Some 
pharmacists early in their career took special care in their presentation. One made it a 
point to tell me he wore a suit that day to work in order to look more professional for our 
interview. I noticed the older and more experienced pharmacists had no such pretences. 
They chose to meet in more informal settings, showed up in jeans and t-shirts, relaxed in 
their seats and were candid and quite frank about the limitations they operated within on 
the job and their frustration in dealing with patients and doctors. Regardless of the level 
of experience or setting a particular pharmacists practiced in, certain themes and 
contradictions regarding patients and prescribers emerged early and are presented herein. 
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Chapter IV: Pharmacists and the addicted body 
 Prescription drug abuse receives increasing attention from researchers, 
policymakers, as well as mass media. Entangled in these multiple discourses are larger 
beliefs about drugs, the medical system, and the body. While the role of doctors in 
patient’s acquisition of controlled, abuse-able drugs is more frequently profiled, scant 
attention has been paid to the professional roles of pharmacists and how their 
conceptualization of drugs, the medical system, and the body can enlighten the debate 
concerning prescription drug abuse.  
 Pharmacists can be classified as paraprofessionals (Freidson 1974:71-84). Their 
work does not entitle them to an equitable amount of agency and autonomy as that which 
characterizes the work of more prestigious medical professionals. The expansion of 
available drugs on the market has coincided with an expansion on the degree 
requirements of pharmacists. Where a four-year degree once was sufficient to run a 
pharmacy, these jobs are relegated to holders of a six-year Doctorate of Pharmacy degree 
(PharmD). Pharmacists may elect to pursue an additional two-year residency requirement 
that enables them to practice in hospitals and other settings where they are involved in 
direct patient care (American Association of Colleges of Pharmacy 2013). Yet, the vast 
majority of pharmacists will be employed by corporate pharmacies where patient 
interaction is brief and they frequently describe succumbing to pressure from corporate 
superiors to increase profits. Thus, pharmacists’ work is segmented into two discrete 
roles. On one hand, they share the care-oriented goals of other medical professionals 
aimed at patient care. On the other hand, however, pharmacists also experience a product-
oriented ethos akin to business.  
	  	  
36	  
 Traditionally, pharmacists dispense medications such as antibiotics that treat 
biomedical conditions. In dispensing these types of drugs, their business ethos are in 
harmony with the medical ethos of patient care. Dispensing the drug (profit) will improve 
the patient’s health (care). However, the growth of pharmaceutical companies has 
introduced new classes of medications to treat a variety of newly defined illnesses. 
Among these new pharmaceuticals are a mélange of medications with abuse potential. 
According NIDA (2011), chief among these abusable medications are Vicodin, 
Oxycodone, and stimulants used in the treatment of ADD/ADHD such as Ritalin and 
Adderall. With the growing attention prescription drug abuse has received in recent years, 
pharmacists are acutely aware when dispensing these drugs of the possibility they are 
dispensing an illegitimate script. An illegitimate script1 may include a fraudulently 
altered script, a script for medication the patient intends to use for the purpose of “getting 
high” or divert through selling the medication to addicts for the purpose of “getting high”. 
When the possibility for abuse exists, the situation brings into conflict several aspects of 
pharmacists’ work and the ethos that direct such labor.  
 This chapter will focus on first describing the nuances of pharmacists’ 
professional ethos and self-described professional roles and how pharmaceutical abuse 
brings several aspects of their work into conflict. While their business ethos stress 
dispensing a product in order to increase profits, pharmacists’ care ethos dictate 
dispensing an addictive agent to an addict is not regarding the patient’s well-being and 
health. Additionally pharmacists describe their role on one hand as “drug experts” 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  For clarity, I will use the term script to refer to the physical paper patients receive from 
their doctor and bring to the pharmacy with indications for how the drug should be filled. 
I will only use the term prescription as synonymous with medication to refer to the bottle 
or pills patients consume.	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conducive to a business ethos. Yet, they also describe their professional role as being 
patient advocates. The latter reflects their care ethos. Pharmaceutical abuse similarly 
brings into conflict these two professional roles. I will argue pharmacists partially 
ameliorate these role and ethical tensions by employing a particular understanding of 
drugs and addiction. This conceptualization sees drugs as agents of fragmentation where 
the addicted person is split into the addict on one hand, and the ‘true patient’ on the other. 
The process of addiction is seen in this conceptualization as enshrouding the ‘true patient’ 
beneath the cloak of addiction and enables pharmacists to navigate the uneven terrain of 
being paraprofessionals straddling business and medicine, profit and care.  
Business versus care ethos. A pharmacist working in a corporate pharmacy in a 
small community somewhat notorious amongst medical professionals in the region for 
prescription drug abuse discussed with me the “business side” of pharmacy. 
“[Pharmacies] will be more successful the more scripts they sell, so pharmacies are trying 
to encourage more script volume…that means more revenue, better business.” Another 
pharmacist described how he has “to be more efficient. It used to be you could be 
profitable doing with one pharmacist and a tech, you’d only need to do about fifty scripts 
a day. Now, you need to do about 200 scripts a day in order to be profitable.” He went on 
to more specifically detail how his previous corporate pharmacy stopped filling for 
certain medications because “we are getting negative margins meaning we are losing 
money on certain scripts that we used to make money on…” Pharmacists experience the 
demand for increased script volume most acutely in their workflow. Pharmacists come 
under increasing pressure to work faster without sacrificing accuracy. However, 
“accuracy” is frequently couched in economic terms. “At one point, the average mark-up 
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on a script was about two percent meaning after we pay our people, after way pay the rent, 
all your overhead, it’s two cents on the dollar. So, you make a mistake on a $100 
medication or a $1,000 medication, you are taking a pretty big loss.” Thus, the cost of 
poor accuracy and efficiency is lost revenue. Losing revenue is antithetical to the 
definition of “good business” proffered by pharmacists. One pharmacist described the 
workflow in retail as unstructured, “all of a sudden rush hour comes along and it’s just 
book, book, book, you go as quick as you can and be as efficient as you can.” Where the 
business of pharmacy dictates increased script volume, pharmacists experience 
unstructured workflow where their accuracy and job performance is judged by the effect 
on revenue. Pharmacists’ “business ethos” is centered on the profit-generating aspect of 
their work and position the individual as a customer, not a patient. 
Business ethos: Pharmacists as drug experts. I have described pharmacists as 
paraprofessionals equally engaged in a set of ‘business ethos’, which essentially product-
centered, while also engaging in a set of ‘care ethos’, goals aimed at patient-care. These 
ethos are not discretely practiced by pharmacists on the job; rather, these two ethos are 
frequently conflated. Pharmacists express their aim of patient-centered care their self-
identified role as “drug experts.” The way in which this role helps to form pharmacists’ 
“business ethos” must be developed here. Kim and Will are pharmacy interns I met in a 
bustling coffee shop in a mid-size Midwestern city. Both had been exposed to pharmacy 
for several years: Kim’s cousin runs an independent pharmacy in Minnesota and Will 
began as a clerk in high school at his local pharmacy. When I asked them what role 
pharmacists have in healthcare, Kim responded immediately, “The drug experts. We may 
not know how to diagnose. I guess we’re tested on it and we’re exposed to it, but that’s 
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not what we learn. You learn they got this; this is what you treat. This is their renal 
functions, this is what drug dose to use.” Will agreed and added, “not just necessarily 
treatment. It’s these deeper, more meticulous, more specific things like the drug lasts 
eight hours in the body, so we gotta dose it every eight hours not every twelve.” 
Pharmacists’ role as drug experts supports the revenue-focused aspect of their work, as 
well as the patient- and care-oriented aspects of their labor. On one hand, their role as 
drug experts extends to patient counseling. The pharmacists I spoke with who practiced 
in independent pharmacies stressed how their role as drug experts was enacted to help 
patients find the cheapest, most effective medicine. One example an independent 
pharmacist I spoke with provided was encouraging patients prescribed Prevacid, an anti-
reflux drug, to talk to their doctors about Tagamat or Zantec, which are significantly 
cheaper. Thus, pharmacists’ role as “drug experts” reinforces their goals of patient-
centered care.  
Yet, their knowledge of medications offers a way to legitimately participate in the 
hierarchy of medicine and intersects with the business-oriented nature of their work as 
well. In speaking with Will and Kim, the pharmacy interns, Will was careful to correct 
Kim when she cited the higher authority of doctors in prescribing medications. He 
retorted, “Well, sorry, they’re the ones prescribing [the medications] but we’re the ones 
verifying whether or not they’re appropriate.” Kim quickly tried to cut in, “I realize that, 
but…” before Will jumped in, saying “It still has to go through us.” Through pharmacists’ 
knowledge of drugs, they are able interact with doctors in a meaningful way by either 
allowing their scripts to be filled or questioning the doctor’s decision making. Thus, in 
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enacting their role as “drug experts” pharmacists can simultaneously be product-
/business- and patient-/care-centered. 
Care ethos. However, pharmacists as paraprofessionals also share characteristics 
in common with medical professions, not only with business. Pharmacists are invested in 
their patient’s health and well-being like other medical professionals. Pharmacists also 
couch their work in terms of patient care. When engaging in this script, the individual is 
treated as a patient. One pharmacist I spoke with described enacting his role as a medical 
professional: “we see the patient/customer the most frequent of any healthcare provider. I 
think considering the fact that people are trusting us, they are going to take something 
that we are giving them and putting it in their mouths and bodies to regulate a condition 
or to help try to maintain health.” In addition to how this pharmacist was acutely aware of 
his connection to patient health, he was also explicit of how the individuals he helps are 
both patients in the medical system and customers of a business. While community 
pharmacists were the only ones to couch their work in these terms, which will be 
expounded upon in a subsequent chapter, all the pharmacists I spoke with were motivated 
to enter pharmacy for patient care and relayed stories to me with pride about instances of 
patients approaching them with questions about their diagnosis or about complementary 
non-medication interventions. All pharmacists expressed a desire to develop relationships 
with patients. Pharmacists’ orientation toward patient care constitutes what I call their 
“care ethos” which simultaneously guide their on the job decision making along with 
their “business ethos” detailed above. 
Care ethos: Pharmacists as “patient advocates”. Similar to their role as “drug experts”, 
pharmacists describe themselves as being “patient advocates”. Pharmacists experience 
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the care aspects of their work through the hierarchical nature of the medical field. The 
fact that prescribing physicians have more prestige, status, and professional autonomy is 
reinforced throughout pharmacy curriculum. In one of the labs I observed, students were 
evaluated on their ability to confront a professor acting as a prescribing physician who 
has made a mistake on a script. Students, acting as pharmacists, were given a patient 
description and the doctor’s script and had to identify the mistakes on the script, which 
could range from a dosing error or an inappropriate drug for the “patient’s” condition. 
Students who scored high marks on the lab were commended on their deference to the 
physician’s authority and providing research gathered from textbooks or PubMed to 
support their suggestion. Once these students enter practice, they likely will have to 
respect the hierarchy in several ways as the practicing pharmacists I interviewed 
described.  
The burden of doctors to increase their patient load and the decreasing amount of 
time doctors have to spend with each patient is well documented (Dugdale, Epstein, and 
Pantilat 1999, Baron 2010). However, how the demand for doctors’ time intersects with 
the role of pharmacists in the day-to-day practice of pharmacy is not as well understood. 
As mid-level practitioners with little to no authority within the medical hierarchy, 
pharmacists rely on prescribers’ authority heavily and in multiple capacities. The most 
pervasive demand for doctors’ time from pharmacists is in checking suspicious scripts. 
However, pharmacists frequently bemoan the inaccessibility of doctors. One pharmacy 
intern described contacting physicians: “So, you call [doctors] and you know all of a 
sudden ‘Oh, I’m with a patient.’ So, they’ll call you back. Well, what do you tell the 
patient that’s standing right in front of you? ‘No, you can’t have your medication right 
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now?’” Pharmacists must get physician approval for anything on a script that is not clear 
or to make any change to a script. They lack the professional autonomy to do so and also 
are encouraged by their companies to shift the onus of (legal) responsibility on physicians, 
including in instances of suspected fraud. One pharmacist who managed a corporate 
pharmacy in a small town told me she “[knows] for a fact that [Corporate Pharmacy X] 
doesn’t allow us to call the police or anything. We have to call the doctor and the doctor 
has to initiate that sort of thing.” Similarly, pharmacists avoided confronting patients and 
prefer to notify the doctor of a problem script to allow them to rescind the script. One 
pharmacist told me how “I try not to deal with the patient as much as I can just because 
ultimately the doctor needs to be involved.” If they cannot get a hold of the doctor, 
pharmacists will defer to other entities with professional autonomy in order to decline the 
patient’s script. One pharmacist described how she has run into “house fires…where 
patients said they had a house fire and they lost everything but they are only looking for 
their narcotic again even though they have diabetes medications, hypertension medication 
and depression medication.” In one such case, the pharmacist researched online to find a 
house three doors down from the patient had burned, leaving the patient’s house 
unscathed. “I called the insurance company and so I wasn’t technically lying to her and 
they said that they would give her diabetes medications and her hypertension 
medications…and the narcotic they said they wouldn’t really do much to help her get 
through.” The hierarchical nature of pharmacists’ work is another aspect of their 
orientation to care over business where they are beholden to the authority and autonomy 
of prescribing physicians or insurance companies in order to conduct business. Thus, 
pharmacists are highly constrained professionals through the medical hierarchy. These 
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constraints define in part their orientation to other medical professionals and to care on a 
broader scale. 
Their second role as care-oriented patient advocates also treads the line between 
pharmacists’ roles as businessmen and medical providers. A pharmacist who runs a small 
town independent pharmacy had been a pharmacist the National Guard for twenty years. 
She continued to live by the motto she learned in the military, “getting the right drug to 
the right patient at the right time.” This slogan reinforces the simultaneous drug and 
patient centeredness of pharmacists’ work. The first pharmacist I spoke with to identify 
her role as “patient advocate” described this as “I’d say we are patient advocates. So, try 
and help get patients the correct medications and also the best prices and ways they can 
afford it, that’s everything. And also safety. Protecting a patient from themselves 
sometimes whether they like it or not [emphasis added].”  
The significance of the prior quote should be properly contextualized. The notion 
that a patient needs protecting from himself or herself has great implications for 
understanding how pharmacists conceptualize prescription drug abuse. In dispensing an 
antibiotic, for example, pharmacist’s business and care ethos are in line. Selling the 
medication simultaneously brings profit and health. However, prescription drug abuse 
problematizes and brings into conflict these two ethos, as the patient’s acquisition of the 
drug enables addiction, a harmful and detrimental state. How pharmacists ameliorate this 
tension is what the remainder of this chapter will focus on.  
Business and care ethos: Problematized by prescription drug abuse. A pharmacist 
told me his professors preached to him to “treat the patient, treat the patient and make 
sure that they are comfortable and happy and satisfied with the care that you give them 
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and make sure that you are helping them out the best way possible.” Yet, he observed a 
“big discrepancy” between the “idealism” propagated in pharmacy school and the 
realities of combating drug diversion. He soon found with regards to the patient dynamic 
promoted in school “working and having real life experiences teaches you that that’s a 
really bad philosophy.” He went on to describe how “you never want to turn someone 
away if they have a real reason for needing something early, but you got to be cautious. 
You got to realize that people are always going to lie.” Thus, pharmacists quickly 
approach their practice facing two fundamentally different kinds of patients: one who 
seeks to legitimately acquire medications for the treatment of a ‘true’ illness and another 
who seeks to illegitimately acquire medications for abuse. In order to incorporate these 
two patient/consumers and the ways in which they intersect and bring into conflict their 
two ethos, pharmacists must re-conceptualize the nature of drugs and how they interact 
with the patient’s identity. Then, pharmacists adopt the view that drugs fragment the 
individual into the ‘true patient’ and the ‘addict’ in order to accommodate both their 
business ethos and their care ethos.  
How pharmacists conceptualize addiction. The way pharmacists discuss the 
process of addiction is indicative of the conceptualization of drugs as fragmenting agents. 
Pharmacists employed two terms to discuss the habituating effects of long-term 
maintenance on drugs: dependence and addiction. Pharmacists describe dependence as 
being both physical and psychological. Physical dependence refers to the processes of 
withdrawal and tolerance. Withdrawal is defined as the onset of symptoms upon 
discontinuation of the drug. The concept of tolerance refers to needing more of the drug 
to achieve the same high, or effect. Psychological dependence is described as a separate 
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but related process. Psychological dependence was described to me as a vague process 
where “your mind just becomes fixated on ‘I need this drug; I need this drug’…their 
body is fine but they’re just thinking, thinking, thinking about it.” The distinction 
between a drug’s physical and psychological effects and the notion that “their body is 
fine” but the addict’s mind is focused on the drug suggests a drug’s capability to create a 
mind/body dualism. Although “addiction” is now the preferred term in the literature, the 
term refers to the same constellation of phenomena as physical and psychological 
dependence. Thus, addiction and dependence are understood as processes by which a 
substance fragments the addict, separating mind from body as well as the autonomous 
control of the mind over the body. 
However, pharmacists carefully delineated dependence from the pejorative 
connotations of the term ‘addiction’. One pharmacist pointed out how it is “hard to prove 
someone is addicted versus in actual dependence. I mean, we know that with any 
medication your body develops a kind of dependence over time. As far as drug abuse, 
that is more of the psychological, that is the craving, the drug-seeking behavior, the ‘I’ll 
do anything to get a fix,’ as opposed to the physical.” Thus, psychological dependence is 
the element that delineates the more general term of ‘dependence’ from ‘addiction’. 
Another pharmacist described “one guy, he gets Vicodin every Friday. We never allow 
him to get it early. So, I say ‘No, you’re due Friday; you can come in Friday’ and of 
course, he’s always there at 9 o’clock in the morning to get it, but he knows! We’re not 
going to fill it early for him and we’re up front with him…Now, that’s a guy that 
probably has a legitimate need for the pain medication but is very dependent on it. [He] 
doesn’t want to run out.” Again, dependence is employed as a general term, not 
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necessarily problematic, alternatively referring to a biomedical, physical process common 
to many medications and an independent psychological state. Thus, the presence of 
dependence does not necessarily make the prescription illegitimate. Dependence in the 
presence of a legitimate health concern is viewed as an expected occurrence of long-term 
maintenance on medication for a chronic condition. Addiction, then, can be defined as 
primarily psychological and pursuit of the drug when it does not serve therapeutic goals. 
A legitimate patient, the ‘true patient’, is one who “knows” they are dependent, as the 
patient in the prior example who attempted to get his Vicodin early. The addict is not 
aware of their dependence on the medication, meaning through the process of addiction, 
pharmacists see the drug as splintering the individual’s biological processes from their 
psychological awareness. For example, one young pharmacist in a small-town branch of a 
corporate pharmacy told me about a patient he encountered early on in his career who 
was picking up a prescription for Suboxone. 
One time when I was first starting out a guy was picking up a drug called 
Suboxone, which is a strip that dissolves under your tongue and it helps if you 
become addicted to a pain medication. It just helps to provide a lower amount of 
that feeling from the drug throughout the day it prevents you from really abusing 
that drug or other pain medications and I was just kind of asking him ‘So, what 
did the doctor tell you about this so far?’ Just trying to counsel him. It wasn’t too 
busy, so I tried to have a good conversation. He seemed interested and everything. 
He really wanted to know all about it. He said, ‘Well, it’s kind of a necessary evil 
right now.’ And I said ‘Oh, okay I think I know what’s going on here.’ And he 
says ‘Yeah, I was taking pain medications for my back and after awhile, I just 
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realized I shouldn’t still be on these but it’s really hard to stop.’ So, that’s why he 
was taking Suboxone. And then, we kind of went through what you can expect as 
a result of taking Suboxone, all the risks you know. You can still be addicted to 
this, but if you follow your doctor’s directions carefully and follow up with him 
and gradually work your way off the Suboxone, hopefully you can get back to 
normal before you get dependent on the [Suboxone]. [emphasis added] 
The pharmacist described dependence as the result of not carefully following doctor’s 
orders, following up with the doctor, and weaning off Suboxone. As described earlier, 
dependence is referring to becoming physiologically habituated to the drug. Here, a 
patient’s compliance and adherence is perceived to be indicative of the awareness and 
will to discontinue Suboxone and other addictive agents. If these behaviors are not 
followed, then the patient is deemed to be unaware of their addiction and not pursuant of 
getting clean. Thus, addiction occurs in the absence of compliance, adherence, and hence, 
awareness. Consequently, addiction is once again viewed as the result of a drug’s ability 
to fragment an addict’s biological processes (the ‘true’ patient) from their psychological 
awareness (the addict). 
In review, as paraprofessionals, pharmacists are alternatively product- and care-
centered. In order for these to not be in conflict, the product (prescription) has to be of 
therapeutic value (treat a legitimate diagnosis). The patient’s awareness is what makes 
the illness legitimate because awareness is the distinguishing element between 
dependence, or becoming physiologically habituated on the drug, and addiction, where 
awareness of dependency is lost. By viewing the addict as essentially two individuals-- a 
biological customer and a psychological patient—the pharmacist can take their care ethos 
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out of conflict with their business ethos. I will now describe this conflict and how this 
understanding of addiction resolves the professional and ethical tensions that arise. 
How ethos combine in pharmacists daily practice. Central to pharmacist’s on the 
job decision-making is identifying the individual on the other side of the counter as a 
‘true patient’ or an ‘addict’. If the patient is ‘legitimately’ in need of the medication, 
pharmacists can pursue their business ethos in receiving the profit in line with their care 
ethos in helping the patient treat his or her ailment. However, the ‘addict’ may be 
physically dependent, but pharmacists view them as psychologically unaware of their 
dependency. This division is what specifically concerns pharmacists about dispensing 
drugs of abuse to addicts. While pharmacists are invested in increasing revenue for their 
pharmacies in line with their business ethos, their care-ethos is brought into conflict. 
Since the drug does not correspond to a ‘legitimate’ ailment, the drug is not seen as 
having therapeutic value although it would ameliorate withdrawal and tolerance. 
Pharmacists describe the difficulties and frustration in handling prescription drug 
abuse from a highly constrained professional position. One pharmacist said it best when 
he stated, “the problem that pharmacists have is we’re stuck in the middle. If it’s a 
legitimate prescription…we’re hard pressed to say ‘No service.’” Another pharmacist 
echoed a similar sentiment in saying, “more often than not, we end up getting stuck doing 
things that we don’t feel comfortable with.” For the trained and well-intentioned 
pharmacist, having to dispense to someone whom they do not believe to have full 
awareness of the possible effects of the medication brings up issues of consent and causes 
them to question whether they are delivering care although generating revenue and profit. 
Thus, prescription drug abuse for pharmacists in a highly constrained position with low 
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professional autonomy who straddle the boundary between business and medicine, 
product and care, brings these two ethos and roles into conflict. 
Pharmacists’ frustration appears in how they often handle patients they suspect of 
abuse but who they are unable to take legal action against or refuse to dispense to. 
Pharmacists often have difficulty in substantiating suspicion of abuse or diversion, 
especially when overburdened doctors may take hours to return phone calls and 
corroborate a prescription. So, pharmacists find other means to hassle patients suspected 
of abusing or diverting medications as both an outlet for their frustration and an attempt 
to find agency in their highly constrained professional position. One pharmacist described 
his “poker face, the front of professionalism. ‘Oh, so sorry that you are in pain right now 
but I need to make sure this leaves correctly, so please allow me a couple minutes to 
make sure I can contact your doctor, get everything accomplished the way he wanted it 
to.’” Pharmacists then will ask for supporting documentation, such as a driver’s license 
that is not legally required. One pharmacist explained the utility of this approach because 
“once you ask for the driver’s license, they’re just like, ‘Oh, it’s in the car.’ Then, they 
don’t come back.” Other times, pharmacists ask the patient for specifics on medications 
or medical equipment such as the volume and gauge of syringes, or simply insist on 
speaking to the doctor over the phone before dispensing. One pharmacist described a 
situation where he did exactly this. 
“Sometimes, it’s just professional fun to mess around with them…there’s usually 
different specifications to a syringe. What volume is needed? What guage and 
what needle length? They’ll just make up absurd numbers…just stuff like that and 
you toy with them…I just try to ask them questions and just make them answer 
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me that they’re not using them legitimately. What kind of syringes do you need? 
Oh, 300’s? Well, I need you to be more specific than that in order to sell those to 
you.” 
These examples clearly highlight the presence of the professional and ethical conflicts 
and frustration that arise in attempting to combat prescription drug abuse from the 
perspective of pharmacists. 
Conclusion. Pharmacists view the drug as fragmenting the addict into two 
individuals—a consumer composed of biological processes, what I call the ‘true patient’, 
and ‘the addict’ characterized by psychological unawareness of these processes—and 
doing so allows pharmacists to partially resolve their conflicts. While they more often 
than not end up dispensing the medication even though they suspect abuse or diversion, 
pharmacists can ameliorate some of the tension that arises. The subsequent chapter will 
expound upon another way pharmacists ease the tension pharmaceutical drug abuse 
creates by viewing the drug as overpowering the individual and challenging the authority 
of doctors by blaming them for abuse. However, first, I will argue for the view that 
pharmacists make a compromise in handling prescription drug abuse in the way described 
here. Merriam-Webster defines compromise as, “settlement of differences by arbitration 
or by consent reached by mutual concession; intermediate between or blending of 
qualities of two different things; a concession to something derogatory or prejudicial.” 
Hassling the patient allows the pharmacist to make their dissent known and they do not 
view this as poor care, but rather “the poker face, the front of professionalism.” 
Pharmacists are essentially able to make a compromise: they generate profit by 
dispensing the script in service of their business ethos as well as the consumer, while 
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hassling the addict to attempt to “make them answer me that they’re not using [the 
medications or medical equipment] legitimately.” While defining addiction as the process 
by which a drug fragments an individual and renders them unaware of their dependence 
is the very source of their immediate conflict in dispensing drugs of abuse, the view 
offers pharmacists a way to compromise between their business and care ethos. In the 
next chapter, I will expound on how this view of abuse also offers the logic to more fully 
ameliorate the ethical and role tensions prescription drug abuse arises. Thus, pharmacists’ 
view of drugs and addiction, as well as the effects of these on the human body creates the 
problem they struggle with but ultimately offers a net positive solution to the highly 
constrained nature of their paraprofession in handling prescription drug abuse. 
In conclusion, I have introduced the nature of pharmacists’ daily work as they 
attempt to navigate two different roles, an employee of a corporate (or for some 
pharmacists, an independent) business and medical care provider. I have described how 
prescription drug abuse brings pharmacists’ roles as drug expert and patient advocate into 
conflict as pharmacists attempt to pursue profit while attending to patient care when the 
medications are no longer seen to provide therapeutic value. I also explicated how 
pharmacists’ decision making is predicated on the view that drugs have the capability to 
fragment the individual into a ‘true patient’ composed of biological processes naturally 
occurring in response to long-term maintenance on pharmaceuticals (dependence), and 
‘the addict’ who is unaware of their dependence. In an analytic framework, pharmacists’ 
construction of the addict is rooted in the contradictions inherent in the problem and in 
pharmacists’ competing interests in generating profit and attending to patient care. While 
the addict’s unawareness is the very factor that problematizes prescription drug abuse for 
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pharmacists, adopting this view justifies pharmacists’ attempts to themselves at creating 
agency through hassling addicts and the continued pursuit of corporate-defined profit-
generating work.  
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Chapter V: Pharmacists and prescribers: Care and pharmaceuticals amidst prescription 
drug abuse 
 In the last chapter, I argued that pharmacists’ work is partially governed by sets of 
business and care ethos. Their business ethos is comprised of the drive for profit imposed 
by the corporate structure in which pharmacists relative to other medical practitioners are 
employed. Additionally, this corporate structure also contributes to pharmacists’ status as 
paraprofessionals making their work contingent upon the superior authority of doctors. 
The hierarchical nature of their work and pharmacists’ place at the bottom of this 
hierarchy makes their position highly constrained with low agency, autonomy, and 
authority. Yet, pharmacists are still invested in the patient’s health and well-being, which 
constitutes their care ethos. On the job, pharmacists similarly describe acting as drug 
experts as well as patient advocates. These roles are sites where their business and care 
ethos are co-existing, meaning these ethos are not discrete.  
Prescription drug abuse brings these roles and ethos into conflict. Pharmacists 
define addiction as dependence without awareness, creating a fragmentation between the 
body and mind of the addict. Thus, in dispensing the medication without a “legitimate” 
diagnosis, pharmacists do not view this behavior in line with their care ethos. Yet, 
pharmacists must contend with more often than not having to dispense medications when 
they suspect abuse. To handle this and reduce the role and ethical tensions pharmacists 
feel, they fragment the individual into a ‘true patient’ and ‘the addict’. Hassling addicts 
provides an avenue of agency, an attempt at bringing awareness of his or her addiction to 
the addict in line with their care ethos, while pursuing their profit-generating work. 
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Yet, the tension between these two roles exists largely with patients and 
constitutes only one tension pharmacists contend with in the course of their day-to-day 
work. Pharmacists’ labor is also inextricably tied to the role of prescribers. While 
pharmacists overwhelmingly blame physicians for prescription drug abuse, in practice, 
they perceive their role as monitoring doctor’s prescribing, seeing a managerial role for 
themselves over prescribers. In order to play this role despite being paraprofessionals 
with limited authority and autonomy, pharmacists disambiguate the medications they 
dispense from the patients receiving those medications. By conceptualizing their work in 
this way, pharmacists are able to establish a “turf” centered on medications and separate 
from prescribers’ “turf” concerning patient care. Patient histories and records legitimize 
to a certain extent their labor both to themselves and physicians. However, pharmacists’ 
orientation to medication catches them in the crosshairs of two competing dialogues: the 
medicalization of addiction, which argues addiction is a disease, not a personal failing, 
and pharmaceuticalization, which is the notion of medications as panaceas for numerous 
states of ill health on one hand, and the language of care and patient interests. 
Pharmacists strictly see the medications as their “turf”, but prescription drug abuse has 
recast some medications as agents of harm, not agents of health. As a result, pharmacists 
regard their interaction with prescription drug abuse ambivalently. As the medical system 
has increasingly become predicated on pharmaceuticals, how professionals absorb these 
new definitions in their daily work has profound implications for the state of prescription 
drug abuse, the discipline of pharmacy and the self. 
 “You don’t have a problem with him forging your signature?”: Prescribers, 
customers, and patients. Tom Wilson was a good friend of the father of a friend of mine 
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and I met him for burgers one weekend afternoon. Tom’s energy and enthusiasm belied 
his age suggested by his decades of experience in community pharmacy. “I can give you 
an example of something that will just crack you up,” Tom told me.  
“A patient who had never been to us before…came in to our pharmacy 
with a prescription from an emergency room from a hospital down the 
road from us, two blocks away. For Vicodin. Maybe 15 or 20 tablets, not a 
whole lot.  
“Now, it’s not signed by the doctor. The doctor forgot to sign it. So, 
the pharmacist said, “I’m sorry, but we can’t fill this. You’ll have to go 
down and get it signed,” which is probably the wrong thing to do. The best 
thing would have been to call and verify and take it as a verbal order and 
be done with it. You know, this guy [is] probably a drug abuser; a guy 
coming in from the emergency room and he’s needing meds, you know. 
That’s why I mean sometimes we can be oh so cautious that it’s wrong. 
And in this case, I think it might have been but anyway, the story gets 
funnier.  
“So, he leaves, you know, kind of shakes his shoulders, shrugs his 
shoulders, and leaves and then he comes back and it’s signed. Okay? This 
pharmacist already didn’t trust this person, so she’s going to call the 
hospital and make sure that he actually took it back there and got it signed. 
So, she calls and wants to talk to the ER doctor. The ER doctor gets on the 
phone. She asks him and he says, “No, I didn’t sign anything.” She goes, 
“Really?” He goes, “Don’t worry. It doesn’t matter. He really does need 
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the medication; just dispense it.” She says, “you don’t have a problem 
with him forging your signature?” He goes, “That doesn’t really matter, 
just go ahead and dispense it; it’s fine.” So then, she comes back and she 
talks to the two of us and I go, “Look, just fill it. You got a verbal order; 
just, you know, sign it off as a verbal [order]. Let’s not make an issue. It’s 
not a big deal.” Again, so we are trying to avoid a confrontation with the 
customer [emphasis added] to say, “So, we just called and you didn’t send 
it back there,” even though that’s the information we’ve received. Anyway, 
we dispense it. The patient [emphasis added] leaves. We pull up another 
signed prescription from this doctor, it’s his signature!” 
Sitting in the restaurant, I wish I could say I was more surprised, but I have heard similar 
such stories for the weeks prior from other pharmacists. I respond, “So, the physician 
really did…” and I do not even need to finish my sentence. Tom jumps in, exclaiming 
with more exuberance and surprise than I can between bites of my hamburger, “sign it!”  
Contained in this one story are several themes key to understanding the care 
pharmacists deliver and what tensions are intertwined with both physicians and patients. 
First, the physician in Tom’s story is portrayed as otherwise preoccupied. Tom 
concurrently introduced the previous story as a humorous one, as well as an example of 
“one of the reasons I get so irritated with physicians.” The tension Tom feels in this 
situation with physicians is both explicit and nearly palpable. Secondary to the fact the 
physician forgot he had signed the script, Tom is also frustrated by the physician’s 
laissez-faire attitude about the patient ostensibly forging his signature. From the 
perspective of Tom, the physician seems to think actually signing and filling the script is 
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a mere hurdle to getting the patient the medication to feel better. The physician’s 
definition of care seems decidedly patient-centered that by extension is interpreted by the 
pharmacist as a sign of professional disrespect. Next and perhaps most obviously, parallel 
to the tension Tom feels with the physician, is the tension between the pharmacist and the 
patron. In sending the patient back to the hospital to get the script signed by the doctor in 
lieu of calling to verify and taking a verbal order in the first place, the pharmacists are 
challenging the patient’s trust. They will call the hospital and verify the prescription 
regardless. Then, these actions by pharmacists are essentially moral. Thus, parallel to the 
tension between pharmacists and physicians, is that between pharmacists and patients. 
Third, Tom easily transitions into and out of referring to the patron as both a “customer” 
and a “patient”. Before the financial transaction, he is a customer, but once money 
exchanges hands, the customer becomes a patient. This fact bears on the final theme of 
this story: pharmacists’ care is essentially drug- (not patient-) centered.  
“Why is it our problem?”: Blame and ambivalence in the turf battles between 
prescribers and pharmacists. From the outside as often appears to patients, the roles of 
pharmacists and physicians appear intersecting and unidirectional; physicians write the 
scripts pharmacists must fill. Pharmacy training deals extensively with the side effects 
and interactions of the different classes of medications. As the number of 
pharmaceuticals on the market has increased over the decades along with off-label use of 
medications, this knowledge has become increasingly complex. However, this brings 
pharmacists with knowledge of the medication, into conflict with physicians who have 
knowledge of the patient and his or her diagnosis. Perhaps the most apposite example is 
one provided by a student pharmacist in her internship. She detailed a battle she was 
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currently undergoing with a physician about dosing with gabapentin. “[The attending 
physician] wants more and more research because he doesn’t believe me…[Gabapentin] 
is not doing anything above a certain dosage…it’s maybe not harmful to the patient; it’s 
just what’s the point of giving them 1200 milligrams extra that they don’t need?...[the 
pharmacist and I] have about five studies…we’re waiting to present it to [the prescribing 
physician].” She and the other pharmacist repeatedly provided the prescriber with 
research supporting their claim to no avail. As in this example, pharmacists’ knowledge 
of pharmaceuticals is the one crucial area on which to challenge doctors’ authority, 
particularly when doctors may be inclined to overprescribe medications.  
As paraprofessionals, pharmacists often must mediate between patients and 
prescribers. In such mediations, pharmacists feel tension both with the addict and with 
the physician writing the script.  Their futility is somewhat quelled towards patients due 
both to the fact pharmacists see them as much as customers as patients, as well as how 
they conceptualize addiction. However, pharmacists continue to feel tension with 
physicians, who pharmacists place primary blame on for the emergence of prescription 
drug abuse. Pharmacists are taught a language to engage with prescribers that reflects 
how they would like to be seen by prescribers and teaches pharmacists to handle the 
tension caused by their unequal authority. In the training program I observed, students 
were taught to make suggestions to doctors without questioning their authority. Pharmacy 
students were encouraged to say things such as, “I understand why you thought that way. 
I was thinking this drug might be better for the patient because…”. On one hand, this 
language reflects the real-life constraints of negotiating on the job, particularly with those 
of higher authority; however, this advice also teaches students how to wield their limited 
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authority and practice within the constraints set by their status as paraprofessionals. 
Avoidance of words such as “but”, which change the tone of the sentence and referencing 
what “might be better for the patient” reinforce the common goal of patient health 
without referencing the power differential that exists between physicians and pharmacists.  
The language training programs encourage their students to employ with doctors 
echoes the “spin selling” Oldani (2004: 328) describes between drug representatives and 
physicians. “Every objection (by physicians, patients, and the general public) can be 
turned around to become a positive selling point, something to be valued and sold for the 
patient’s benefit” [emphasis in original]. Oldani describes how the doctor’s initial 
objection may have been a “language game” to see if he, as a drug representative, would 
“be nasty towards the competition, usually not a good idea (the doctor and the 
competition may be golfing partners)” (2004: 328). Pharmacists were taught to elicit 
objections from prescribers and explain how another treatment regimen may better serve 
these ends without necessarily contradicting the doctor. Whether the adoption of this 
technique from the pharmaceutical industry was intentional or not on the part of faculty 
in a pharmacy training program is tertiary to the manner in which pharmaceuticals and 
their effects are actively shaped through language and social exchanges always couching 
these effects as in the patient’s, not the pharmacists’, industry’s or prescribers’, best 
interest.  
Often belied by the non-accusatory language they are taught in school and when 
not engaging with prescribers, the pharmacists I spoke with unilaterally placed primary 
blame on physicians for the acceleration of prescription drug abuse. While their 
admonishments of society or patients were often vague and ill defined, pharmacists were 
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verbose with their blame of prescribers they see as abusing their authority. Tom, the 
pharmacist in an independent, community pharmacy for decades, wondered, “what’s 
going on in that office visit? What’s that person telling you [the doctor] and what are you 
believing? Sometimes, I think, ‘How naïve can you be, Doctor so-and-so? How can you 
think this is legitimate?’” Along these same lines, one pharmacist comically described 
what he calls “get-the-hell-out-of-my-office scripts, where they’ll write like five 
Hydrocodone just to get ‘em out. It’s like, ‘Oh, well it can’t hurt them because it’s not 
enough Tylenol for a daily dose. So, here’s five Vicodin. Go find another doctor.’ You 
see a lot of that.” Another pharmacist referred to scripts for small amounts of Vicodin as 
“calling-your-bluff scripts. ‘I don’t really believe that story you [the patient] are telling 
me but I’m just going to give you a couple to appease you.” Pharmacists perceive such 
scripts for small amounts of abusable medications as irresponsible on the part of 
physicians and an affront to their professional duty. 
Specifically, pharmacists regard such behavior on the part of prescribers to be an 
offense because they perceive such script-writing as an attempt by physicians to place the 
onus of responsibility on pharmacists for filtering out such patients who may be 
attempting to game the system. Because five Vicodin is not enough to be considered 
problematic prescribing and pharmacists have access to a kind of pan-record of patients’ 
medication history, pharmacists believed physicians to be pushing responsibility and thus, 
liability onto pharmacists for dispensing to a patient who may have a record of multiple 
fills of abusable medications. Whether prescribers have this intent is tertiary to the fact 
pharmacists conceptualize their role in healthcare as monitoring both prescribers and 
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patients. One pharmacist phrased this responsibility of managing physician’s prescribing 
as “making sure that every doctor is prescribing within their practice limits”.  
While pharmacists bemoan this responsibility, their language implies a perceived 
“managerial” role above physicians. This claim is emboldened by what one pharmacist, 
Ben, described as the culture surrounding abusable prescriptions as one of apathy on the 
part of doctors. “Who carries the burden of responsibility?” I asked him. Without a 
moment’s hesitation, he retorted, “Doctors. No doubt, it’s the doctors…I definitely put a 
lot of the blame on doctors.” While he conceded that doctors frequently lack the time to 
spend with patients, he thought doctors lacked “people skills” to give patients “insight” 
into their prescribing and recommendations “as opposed to when I tell a patient to do 
something, I say, ‘this is why I want you to take this. This is why I want you to do this. It 
may seem unorthodox, but this is why I’m telling you to do this.’” Ben simultaneously 
and explicitly notes the blame pharmacists place on doctors for prescription drug abuse, 
as well as the closeness he feels he has with his patients. However, it is the 
paraprofessional role of pharmacists that allows such “closeness”. Implied by such 
statements is the fact that the proliferation of prescription drug abuse problematizes the 
professional relationship between pharmacists and prescribers. Pharmacists couch the 
problem as an opportunity to have oversight over doctors, reorganizing the typical 
division of labor. While physicians would refute this perception, the trick of perception 
has limited functional utility, but is a psychological tool by which pharmacists cope with 
having low professional autonomy and authority. 
While pharmacists profess they have a duty as part of their profession to monitor 
physician’s prescribing, they do not perceive this duty as allowing them to shoulder any 
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blame for the problem. Instead, they are quite critical of prescribers. Their blame serves 
two ends. Blaming physicians aids pharmacists’ moralization of patients. By constructing 
a dichotomy through blame—pharmacists versus physicians—pharmacists are able to 
imply their work is more moral and in better service to the “true patient,” even if 
physicians do not recognize, as pharmacists accuse, that they are actually prescribing to 
addicts. Physician blame also serves to set the boundaries of their profession. Such 
accusations bolster pharmacists’ perception of a lack of education among physicians on 
medications. One pharmacist told me “doctors are really good at diagnosing, that’s what 
they are really good at, working with the patient one-on-one to figure out what the 
problem is,” carefully talking around a perceived lack of knowledge pharmacists believe 
doctors have concerning medications. Another pharmacist went more in depth about the 
different “turfs” doctors and pharmacists occupy,  
“I don’t…no, I don’t think, doctors have adequate training on medications. 
I think though what you’ll find is if you took the average, say internal 
medicine doctor. Internist, okay? And ask them routinely, how many meds 
do they prescribe? I bet it’s less than 50. I mean, there’s 10,000 drugs on 
the market; they don’t prescribe 10,000 different products. Mostly, they’ll 
have a very small group of medications that they prescribe. And you know, 
I could probably name most of them right now, the anti-hypertensives, 
drugs for cholesterol, drugs for diabetes… But most 
doctors…don’t…prescribe outside of their comfort zone. So they do keep 
it close to the vest, I think. Cuz they…you know, they’re trying to do a 
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good job, too. You know? So they don’t want to start prescribing stuff that 
they’re not too familiar with.” 
As this pharmacist alludes to, pharmacists consider medications their domain and resent 
physicians they feel misprescribe certain classes of drugs. In blaming physicians for 
prescription drug abuse, pharmacists effectively disambiguate the medications from the 
patient. Pharmacists effectively maintain their claim to medications being in their domain, 
but leave responsibility for both the ‘true patient’ and the addict within the bounds of 
prescriber’s professional realm.  
Yet, pharmacists alternately express reluctance at taking on a larger role in 
combating prescription drug abuse while bemoaning their lack of professional authority 
and autonomy to enact their will. Due to this, pharmacists conceptualize a key role for 
themselves in healthcare as monitoring patient’s consumption and use of medications. 
Part of enacting this role is monitoring doctor’s prescribing. Pharmacists exist, in one’s 
own words, to get “the right drug to the right patient at the right time.” Pharmacists must 
be capable of challenging doctors or patients when either contradicts this dictum. Yet, 
pharmacists must rely on doctors to write prescriptions and patients to patronize their 
business. One of the few avenues pharmacists have to autonomy on the job is deciding 
whom to appease and whom to antagonize. Their ambivalence allows them to alternately 
criticize and rely on physicians and patients as necessary. Ambivalence, along with 
blaming prescribers, then becomes a tool, unique to paraprofessionals, for pharmacists to 
create professional distance from patients or prescribers who may attempt to challenge 
their limited authority. The distance created through ambivalence and blame allows 
pharmacists to carve out their “turf” in the professional landscape. They see physicians’ 
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realm as patient treatment outcomes and their “turf” as monitoring the flow and 
consumption of pharmaceuticals. By regarding both prescribers and patients ambivalently, 
as well as blaming prescribers, pharmacists attempt to set the bounds of their profession, 
legitimizing their position in the medical hierarchy, and constructing their own values 
system.  
Pharmacists adopt a similarly ambivalent attitude towards prescription drug abuse 
and diversion. Every pharmacist I spoke with had at least one instance where they 
recounted an abuser they reported to a prescriber. Pharmacists recount these stories with a 
sense of pride and at times, their body language while retelling these stories would hint at 
feelings of superiority over doctors in their ability to detect these instances of abuse. First, 
pharmacists have the ability to work with insurance companies to see if a patient has 
received the same medication in the recent past. As I described earlier, pharmacists feel 
physicians rely on them to thwart patients who “doctor shop” for their medication, 
referring to the practice of visiting several prescribers seeking multiple prescriptions for 
the same medication. Of course, this strategy is limited to patients with insurance. For 
those without insurance or state aid, pharmacists still have exclusive access to all patient 
histories, a kind of pan-medical record of patient’s prescriptions. However, more often 
than not, pharmacists end up dispensing abusable medications and in this case, patient 
histories are the only record they have of their suspicions. Pharmacists I spoke with were 
adamant in their support for prescription drug monitoring programs, which would 
increase the control they have over whether to dispense medications or not by providing 
them with a complete record of each individual’s prescriptions, making it easier to catch 
“doctor shopping” and similar behaviors that flag abuse. Such monitoring programs 
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increase pharmacists’ professional autonomy and control over their product, key factors 
in the development towards full professionalization.  
While pharmacists enthusiastically supported prescription drug monitoring 
programs and expressed desire to achieve greater autonomy and control on the job, they 
quickly backtracked when discussing such drug monitoring programs in the context of 
prescription drug abuse. Overall, pharmacists’ attitude towards intervening in 
prescription drug abuse could be described as ambivalent as well: they prized moments 
when they were able to challenge doctors’ authority and call the prescriber’s attention to 
a patient who was “doctor shopping” and welcomed the emergence of prescription drug 
monitoring programs, but were steadfastly resistant against taking on any role to formally 
intervene in the problem, saying it is the fault of doctors and doctors must resolve the 
problem. Their ambivalence allows pharmacists to challenge doctors by assigning them 
blame for prescription drug abuse in seeing it as a ‘patient problem’ (not a ‘drug-
problem’), but maintain their perceived role as monitoring both patient consumption and 
physician prescribing. Together, these views, although seemingly contradictory, allow 
pharmacists to insulate themselves from accepting the blame for prescription drug abuse. 
One of pharmacists’ most fundamental doctrines is that addiction is created by a patient’s 
use, not the chemical properties of a pharmaceutical. In seeing doctor’s “turf” as patients 
and addiction the result of bad patients, pharmacists are able to maintain the sovereignty 
of doctors over their patients, insulating themselves and the pharmaceuticals from being 
viewed as the agents of addiction. 
Pharmacy records in legitimating work and in coping with frustration. 
Pharmacists currently have access to records within their chain of every person who has 
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filled a script at any location in the country. Pharmacists can also add subtle notes if they 
suspect a patient is abusing. One pharmacist described including these notes: “We try to 
keep comments on profiles. We have to be really professional about this. We can’t say 
something like ‘This patient will scream and yell if you don’t let their medication go 
early.’ You can’t write stuff like that. What we have to say is like ‘Watch for early refills. 
Watch Lorazepam [Ativan, a commonly abused anxiolytic] use.’ Stuff like that. That’s 
how we have to try to go about that.” Thus, such records contain not only a history of the 
patient’s business transactions, but also of communication with patients and whether the 
patient is suspected of abusing or diverting their prescriptions. 
The role of pharmacists’ records and the kind of record prescription drug 
monitoring programs offer should not be understated for its role in legitimizing 
pharmacists’ knowledge and work. While their ambivalence legitimates their position in 
relation to physicians and patients, their records play an important role in legitimating 
their work, particularly when they suspect abuse but are unable to keep from dispensing 
the medications. Many times, pharmacists told me instances where they had to dispense 
potentially illegitimate prescriptions, “you document the heck out of it. Just document the 
snot out of it in case somebody comes back, in case there is a lawsuit, in case there is an 
audit.” First, such records provide a perceived unbiased perspective on which to 
challenge doctors and physicians when their professional position alone does not warrant 
such antagonism. Second, patient’s history also legitimizes pharmacists’ work by 
providing a record of their labor and patient interactions. Pharmacists come into contact 
with patients only briefly and are usually left unaware of patient health outcomes. Patient 
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records provide an inventory of their labor and a tangible artifact of their efforts at 
recognizing abusers.  
In the milieu of Brodwin’s description of an “assemblage of compliance”, such 
records compose an “assemblage of awareness” (2010: 130-1). The definition of 
assemblage he provides is astute, “a whole constructed of heterogeneous parts that retain 
their distinctive identity…the notion of social assemblage insists that the various 
components do not really aggregate; they come together contingently at particular 
cultural and historical periods.” (2010: 130). The patient records unique to a particular 
pharmacy chain and Prescription Drug Monitoring Programs (PDMPs), which at their 
most fundamental function collect these records from all pharmacy chains, are constituted 
by disparate components from different pharmacists and different settings detailing all 
aspects of pharmacists’ exchange with patients. The medication(s) a patient receives, 
recommendations and instructions for their use (i.e., “take this food”) and suspicions (i.e., 
“watch Lorazepam use”), as well as if contact with police and law enforcement are made 
can all be combined in this one data source. For such problem cases, pharmacists’ hope is 
that this will facilitate prosecution should a patient demonstrate an ongoing pattern of 
behavior consistent with drug-seeking or at least absolve them of legal, if not ethical, 
responsibility for dispensing in such situations. The ultimate goal of these is for them to 
accumulate a tangible show of problematic behavior to encourage the patient to become 
aware of their irresponsible use perhaps in the pharmacy or in the courthouse. Since 
awareness is the key factor delineating problematic addiction from mundane dependence, 
this assemblage of awareness is the last vague hope pharmacists have of combating 
prescription drug abuse.  
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After all, even when pharmacists are able to positively identify an abuser and call 
the police, pharmacists make a costly time investment, which they see contradictory to 
both their care- and business-centered ethos. One pharmacists told me a story where he 
dispensed Ativan to a patient he suspected of abusing, just to have another customer 
come into the store and tell him he was trading the medication for cash in the parking lot.  
“You go to all this work, you waste an hour like calling the police 
department “Alright, I need a case number.” You call the doctor and say 
“Hey, I have this case number where this patient’s medications were 
stolen and his son came into his house and beat him up is what the guy 
said.” And then you get doctor’s approval to let it go, state approval to let 
it go, police work…it takes a lot of time! And that holds you back from 
being able to help other people too. And, just to hear that it went out 
means…I mean, someone described the hat he was wearing, clothes and 
everything and yeah, he was just talking to another guy, handed him a bag, 
and took a bunch of cash and…that was frustrating.” 
Despite pharmacists’ best intentions, they often have only a note in a patient’s profile of 
their time spent following up on the problem. As the quote implies, the work is 
frustrating both in its fruitlessness, as well as the fact it fails to serve either care- or 
business-centered goals. In documenting not just a financial transaction, but a record of 
what was dispensed or discussed, and sometimes their suspicions of a patient’s abuse in 
muted terms, pharmacists are at least able to align themselves with traditional care-
oriented goals through these records enabling them to make appeals to doctors in the 
name of the patient’s interest to not dispense in cases where they believe a patient should 
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not receive medication. Additionally, such records are often the only outlet for 
pharmacists to express their frustration albeit in restrained terms at dispensing to those 
they believe have illegitimate intentions, helping to legitimize their work to themselves. 
Prescription drug abuse: Shifting the definition of care. In summary, pharmacists’ 
blame of prescribers for prescription drug abuse creates a schism between pharmacists 
with knowledge of pharmaceuticals, and prescribers trained in patient care. Pharmacists 
are able to establish a “turf” for themselves as managers and monitors of physician’s 
prescribing and patient’s consumption of medications. In adopting the dictum that there 
are no bad medicines, only bad patients, pharmacists are able to separate blame and 
responsibility for the problem from the medications and their challenges to doctors’ 
authority. Adopting this ambivalence legitimizes their status as paraprofessionals, largely 
dependent upon the work of prescribers and seeking greater autonomy and authority, but 
not taking on blame or responsibility for a problem they define as a problem with patients 
and thus a doctor’s concern. Patient histories and the notes pharmacists include provide a 
material link at their effort to boost their attempts at adopting more authority and 
autonomy through identifying abusers and stopping the flow of medications to these 
individuals; attempts that frequently prove futile to the great chagrin of pharmacists. Such 
records are an invaluable tool for pharmacists to legitimize their efforts, at least to 
themselves. Instead of making attempts to increase their professionalization per se 
through combating prescription drug abuse, pharmacists seem to be challenging the 
supremacy of prescribers and physician’s definition of care in prescribing to addicts. 
Amidst their attempts at combating prescription drug abuse, pharmacists must 
maintain healthy working relationships with doctors of higher authority because doctors 
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provide pharmacists with a potential powerful ally against a problematic patient. I have 
already described how pharmacists often have the knowledge of a patient’s history used 
to identify “doctor shopping” and potential abusers to physicians. Yet, it is the relatively 
rare occasion when pharmacists are able to use this knowledge without referring to the 
authority of a physician or insurance company to deny dispensing medications. However, 
mostly, pharmacists dispense medications in such situations, feeding their alternating 
reliance and frustration towards prescribers, or their ambivalence. One pharmacist 
expressed the anger that results from such futility in saying “pharmacists get real 
frustrated like, why is it our problem? You know, why do we have to be the police?” 
While, it is certainly true this work falls to pharmacists as paraprofessionals to do the 
“dirty work”, the futility pharmacists frequently experience on the job and their 
ambivalence towards prescribers suggests a fundamental disconnect worth exploring 
between pharmacists and prescribers: a disconnect between pharmaceuticals and patient 
care.  
While pharmacists steadfastly see medications as benevolent and instead cast 
individual’s use of medications as harmful, prescription drug abuse has nevertheless 
redefined medicines as not only agents of health, but also as agents of harm. In this way, 
pharmacists’ work in dispensing such medications is often antithetical to patient care and 
treatment outcomes, aspects largely defining doctors’ work. Then, pharmacists are 
brought into professional conflict with physicians and medications are brought into 
conflict with patient care. The tension between pharmacists and prescribers mirrors this 
tension emerging between medications and patient health. 
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For the purposes of this work, care is defined as an iterative, individualized, 
holistic and actionable (versus moral) process, which involves the patient as active 
subjects (Mol 2008). This idealized version of care can be contrasted with a “second 
logic of care” emphasizing patient choice and which views patients as consumers. While 
one logic of care involves the patient in defining the standard, “what follows is that for 
the logic of care gathering knowledge is not a matter of providing better maps of reality, 
but of crafting more bearable ways of living with, or in reality” (Mol 2008:46). The 
transaction of pharmaceuticals in exchange for a doctor’s script and money is inherently 
economic in nature and lends itself to the second logic of care Mol details. Yet, when the 
very product meant to deliver care in shifting contexts becomes an agent of harm, these 
two logics intertwine and often, strictly contradict each other and new facets to the 
definition of care emerge. 
Unlike prescribers, pharmacists deal much more extensively with medications, 
especially with patients’ use of medications via side effects or contraindications. 
Pharmacists appreciate opportunities to educate patients on medications and feel they 
have a role regarding patient care as patient advocates. The way one pharmacist I spoke 
to described her role in the medical hierarchy reflected the potential for conflict in 
enacting this role with patients. “I’d say we’re patient advocates…protecting a patient 
from themselves sometimes whether they like it or not.” Implied in these words is the 
necessity of antagonizing patients. “We have the information to help people to try and 
take medication properly. Taking medication improperly can be as harmful as it can be 
beneficial,” one pharmacist extolled his skills. As these quotes suggest, pharmacists view 
pharmaceuticals as inherently health-promoting; an individual’s use of the medication 
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determines whether the substance is harmful or healthful. Put another way, there are no 
bad medicines, only bad patients. 
In the same way pharmacists have adopted this dictum, the dialogue of 
prescription drug abuse has adopted an insular attitude towards the products of major 
pharmaceutical corporations. The medicalization of addiction created the notion of 
addiction as a disease, instead of the result of personal moral failings. Pharmacists 
absorbed this thinking in conceptualizing the ‘true patient’ as opposed to the addict. 
However, as the breadth of pharmaceuticals came to include ones capable of producing 
potent, addictive effects, pharmacists along with the rest of the medical community as 
well as society as a whole, continue to contend with the medications we have come to 
rely on being powerful agents of harm. Pharmacists grapple with the changing context of 
pharmaceuticals from curative agents to agents of harm in their daily work. On one hand, 
medications are viewed by pharmacists as inherently benevolent, addicts as victims of a 
disease, but a disease caused by medications they are believe to be wholly health-
promoting. Thus, pharmacists’ ambivalence is the result of a wider ambivalence 
emerging around prescription drugs. To gain increasing control over the product and 
achieve more professional autonomy would accompany accepting responsibility for a 
tension yet to be resolved.  
 As in the story to introduce this chapter, pharmacists represent a medication-
centered approach to care brought into conflict with physician’s patient care-centered 
paradigm. Similar to how Tom conveyed tension with the patient, pharmacists are unsure 
to a certain extent how to incorporate the prescription drug addict into their daily practice 
and thinking. While pharmacists desire more professional authority and autonomy, they 
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are constrained in how to combat the problem. They use language unique to their position 
as paraprofessionals to either couch their work as business by referring to individuals as 
“customers”, but once money has exchanged hands, they easily refer to the customer as a 
“patient”, switching their script. Since the only recourse of action they have to combat 
prescription drug abuse centers around how to keep medications out of the hands of 
suspicious patrons, once they dispense the medication, pharmacists are able to see the 
individual as a patient. Since pharmacists’ care is medication-centered, they have the 
opportunity to provide their version of care only after the medication has been dispensed. 
Tom’s story of the patient filling a script for Vicodin contains the tension he feels with 
prescribers, as well as patients/customers, and how they conceptualize care. Pharmacists’ 
ambiguity regarding prescription drug abuse reflects a deeper and wider tension existing 
between their conceptualizations of medication and care. 
Conclusion. In instances of abuse, the patient becomes a site wherein pharmacists’ 
care and business ethos are brought into conflict. Despite the low professional authority 
or autonomy of pharmacists, they find ways to gain agency to enact their own moral code 
and in so doing, help ameliorate the tension between their two roles. Pharmacists can 
choose to detach from patient care by removing the label of “patient” entirely and 
categorizing patrons as addicts or portraying them merely as consumers or customers. 
Doctor blaming challenges the position of doctors and allows pharmacists to assert their 
authority, at least to themselves, in the face of the futility caused by having to dispense 
abusable medications to addicts—an act pharmacists see as contradictory to care. 
Physicians are regarded both by pharmacists and in the professional literature as full 
professionals, whose efforts are directed at patients towards offering care in the form of 
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better health. Pharmacists’ position as paraprofessionals equally situated at the interstice 
between care and profit must redefine the meaning of care. How pharmacists define care 
in light of these competing ethics has implications for how they conceptualize and handle 
prescription drug abuse. In other words, pharmaceutical drug abuse requires pharmacists 
to re-imagine their definition of care.  
 Pharmacists’ view of their work, and the ethics that guide it, allow them to 
antagonize patients and refuse to dispense and cast it as care, particularly when taken in 
light of their definition of addiction as splintering the mind from the body of the addict. 
Pharmacists often dispense medications when they do not believe they should. Patient 
histories legitimize this labor and allow them tangible proof to fight physicians’ 
prescribing and combat the futility of operating with low professional autonomy. 
Pharmacists are rarely aware of patient treatment outcomes, although they feel invested 
in the impact of medications on patients’ health, so pharmacists create a distance between 
their role in healthcare and the patient, disease, and treatment outcomes. Care is re-
defined as knowledge of pharmaceuticals and the laws that govern the dispensing of these 
drugs.  
 In summary, pharmacists feel great tension with prescribers. By disambiguating 
the medications they dispense from patients, pharmacists can legitimize their blame of 
physicians by moralizing patients and viewing drugs as inherently health-promoting. 
Patient histories and records provide justification for challenging physicians on scripts 
and play a key role in allowing pharmacists to blame physicians, connecting physicians to 
patient care, and providing pharmacists an outlet to express their true suspicions when 
they dispense to people they suspect are abusing or diverting their prescriptions. 
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Pharmacists’ care is medication-centered, but prescription drug abuse has recast 
medications as potential agents of harm. While medications have been heralded in 
modern medicine as the panacea for any array of health problems, trends of 
medicalization have promoted the view of addiction as a disease, not a personal moral 
failing as it was historically viewed. The ambiguity pharmacists have towards their work 
and the tension pharmacists as medication-centered paraprofessionals feel with 
physicians, as professionals in charge of patient care, reflect the tension existing between 
these two competing dialogues: pharmaceuticalization and prescription drug abuse, 
medicines and patient care. 
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Chapter VI: Conclusion 
 The presence of competing dialogues—between medicalization and prescription 
drug abuse, medicines and patient care—is replicated in other contexts. The University of 
Wisconsin Pain & Policy Studies Group continues research advocating for increased 
accessibility to prescription narcotics for non-terminal patients. While the group publicly 
announced in April 2011 they would no longer accept payouts from pharmaceutical 
companies (Fauber 2011b), life goes on for David Joranson and Aaron Gilson, still 
prominently employed by the group according to its website. Daniel Lee, the drug dealer 
who robbed several area pharmacies in the backyard of the UW Pain & Policy Studies 
Group, is still serving his sentence and will not be set for release until 2078, meaning Lee 
will have to survive to the unlikely age of 115 in order to live free again (USDOJ 2013). 
Yet, larger questions about the conflicts between patient care and the potential for 
prescription narcotics to produce addiction linger.  
 For pharmacists, these tensions become ingrained in their day-to-day work. In our 
discussions, discerning legitimate scripts from illegitimate scripts is a regular process and 
these categories have no clear-cut boundaries. Instead, levels of legitimacy exist 
depending on the patient/customer and the script itself. Pharmacists must strategically 
infer these clues from a set of everyday knowledge garnered through years of formal and 
informal training to make such decisions and in order to hypothesize the fate of the 
medications once they leave the pharmacy and enter the community. Based upon the 
regard for pharmaceuticals gleaned from both their formal academic training and society-
wide beliefs, pharmacists regard their job in producing a bottle of pills for a script and 
money more than merely “pill counting” but a moral act. When all medications are good, 
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pharmacists see it as their fundamental duty to keep the good medicines out of bad hands. 
Yet, their actions so often fail their objectives.  
 It may seem easy to simply cast the actions of pharmacists as unique and their 
inability to keep prescriptions out of the hands of abusers simply a professional failure. 
However, increasing trends of prescription drug abuse demand a more thorough analysis. 
Perhaps in some part either large or small, this trend is fueled by direct to consumer 
marketing creating substantial demand for prescriptions among the public. From this 
perspective, the medical system, not only pharmacists, is constrained by 
pharmaceuticalization. Phamaceuticalization refers to “the process by which social, 
behavioral, or bodily conditions are treated, or deemed to be in need of 
treatment/intervention with pharmaceuticals by doctors, patients, or both” (Abraham 
2010: 290). Patients expect prescriptions because medicines are equated with care and the 
absence of pain or inconvenience. Doctors who prescribe, as well as pharmacists who 
dispense these medications are continually caught between good intentions rooted in 
patient care on one hand and economic and customer demands on the other. 
Pharmaceuticalization has made prescriptions, of which increasing numbers are patented 
each year, a social sign of care and concern. When medicalization produces diagnoses for 
any kind of pain or discomfort, the dispensing of pharmaceuticals becomes a primary tool 
to express care more generally.  
 The idea of pharmaceuticals as agents of care and concern that emerge from 
trends of medicalization and pharmaceuticalization is supported by epidemiological 
trends showing the vast majority of prescriptions individuals abuse are acquired through 
friends or family members who share their prescriptions. Pharmaceuticals as currency for 
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care extends beyond those with formal medical training, but are pervasive as a more 
general societal value. 
 Review of my argument. Pharmacy, drugs of abuse, and addiction share a long, 
intertwining history. Drugs such as heroin and cocaine were once medicinals used 
legitimately among the well to do to treat several illnesses. As these substances became 
associated with the world of leisure and particularly minority and immigrant populations, 
increasing legal penalties prohibiting their use reinforced the existing social order (Acker 
2002:2-9). Addiction emerged as a medical diagnosis in the early 1900’s amidst these 
increasing drug penalties. Such laws did little to slow the productivity of new drug 
development. A variety of drugs and methods to produce them in large scale developed in 
the first half of the 1900’s. Certain drugs, such as the birth control pill, heralded eras of 
social change like women’s liberation (Gordon 2002). In this case, the ability of a woman 
to control her fertility by a self-administered and discreet pill essentially constituted an 
act of social revolution. By 1959, over half a million American women were receiving 
the pill for contraceptive purposes producing large profits for G.D. Searle and Company. 
The notion that drugs could be symbols of social power was well embedded in the 
American psyche, and debates concerning birth control continue today. By the 1970’s, 
the Controlled Substances Act was passed that attempted to establish set prescribing 
patterns. In allowing certain drugs to be automatically refilled without needing a doctor to 
write a new script and in combination with the deinstitutionalization movement heralded 
a new pharmaceutical era (Szasz 2007). Demand for these drugs fueled drug development 
by pharmaceutical companies. The emergence of Prozac in 1977 for the treatment of 
depression ushered record profits for the pharmaceutical industry and other companies 
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worked on developing their own version of Eli Lilly and Company’s discovery (Healy 
2006). Among these discoveries was hydrocodone that, when combined with 
acetaminophen, not only proved to be an effective analgesic, but a less tightly regulated 
Schedule III drug, bringing billions to Knoll Pharmaceuticals. While the drug was 
originally developed for use in terminal cases, in 1985, opinions began to emerge that 
such drugs had a therapeutic utilization among non-terminal patients. One such article 
described “opiophobia” among physicians that causes them to underprescribe opiates, or 
narcotic analgesics. “As a result of this practice, many patients undergo needless pain and 
suffering. Equally important, failure to use these drugs appropriately undermines the 
physician-patient relationship” (Stimmel, 1985). These words explicitly state the 
professional duty of those in medicine is to absolve pain and the value of drugs such as 
Vicodin to enhance the relationship between patients and their doctors. Ostensibly, the 
underutilization of opiates was tied to the illicit nature of related drugs such as heroin, 
heavily racialized and stigmatized dating back to its emergence among minorities and 
immigrants in the late 1800’s.  Like psychiatric diagnoses, pain is a state of suffering not 
readily translated to the atomized and materialistic terms of biomedicine. Pain can be a 
global complaint, not limited to one body part, and no swab or culture can prove its 
existence. A diagnosis of pain is based entirely on patient self-report and a doctor’s 
recognition of this complaint and counteraction of writing a script for Vicodin to 
ameliorate this pain constitutes an act of care for which no other alternatives may exist. 
Drugs and particularly opioids are not value-neutral; instead, their prescribing, dispensing, 
and consumption constitute a social and moral act. 
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 Pharmacists see these dramas play out in their daily work, as documented herein. 
They operate within constraints set by their paraprofessional role, as well as the demand 
for profit and general desire to provide care and ameliorate illness. However, when 
required to dispense drugs of abuse to those they suspect are abusing, the social and 
moral power they view drugs as having becomes ever more salient. While all patients 
habituated on a drug will develop dependence, tolerance, and withdrawal, they claim, 
addicts are in denial about these effects of the drug on their body. As part of this dialogue, 
the conceptualization of drugs as agents of health and prosperity remain intact; addiction 
is a disease of the brain, more specifically of a brain-body disconnect. Pharmacists are 
purveyors of the universal good: medications; however, they see prescribers as laying 
professional claim to patients. Then, pharmacists as not-full-professionals are able to 
fully lay the blame for prescription drug abuse at the feet of physicians. Pharmacists are 
able to attempt to pursue their care-oriented goals by hassling those individuals they see 
as not worthy or deserving of the medications. Meanwhile, they produce an assemblage 
of patient records, often compiled into a Prescription Drug Monitoring Program 
(PDMP)—a tangible record of their negotiations between the often-competing interests of 
doctor, patient, and pharmacist. Providing this semi-public show of their work and 
suspicions of abuse is useful in the face of the futility of attempting to fight the 
proliferation of pharmaceutical agents. 
 Although they place heavy blame on physicians for prescription drug abuse, 
pharmacists also must rely on physicians to predicate their work. Ambivalence emerges 
allowing pharmacists to effectively carve out their professional turf in the face of low 
authority or autonomy to formally do so. A decidedly medication-centered approach to 
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care emerges. Not only are medications the primary object of pharmacists’ work, but they 
provide the means of profit and their therapeutic effects satisfy pharmacists’ well-
intentioned goals towards patient care—a key difference between full professionalization 
according to Freidson (1974:71-84). However, when dispensing to addicts, perceived as 
bad patients who lack awareness of the powerful effects of drugs, pharmacists face 
competing dialogues: medications they are heavily invested in as therapeutic agents 
become agents of disease. Yet, the receipt of these drugs constitutes a powerful and 
pervasive definition of care bolstered by a history of drug-driven social change and gross 
expansion of the market for pharmaceuticals. 
 Pharmacy becomes a key site for these dialogues to occur. Pharmacists’ labor is 
more explicitly business-oriented; as paraprofessionals often physically located in 
business sectors outside of hospitals or clinics, they are without many of the trappings of 
physicians and their professional codes of patient care as a higher order value, and 
pharmacists are explicit in their pursuit of profit in the name of healthcare. Their training 
and labor is centered upon the drugs themselves, not their effect on patient outcomes. 
Pharmacists essentially exist betwixt-and-between business and healthcare and the fully 
professional world of prescribers and the community of patients and customers. 
 While the constraints pharmacists operate within are readily identifiable as part of 
their paraprofessional role, they are not unlike the constraints imposed on society at large 
from which an increasing demand for such drugs exists. If the pharmaceutical market is a 
zero sum game between medical professionals attempting to keep abusable prescriptions 
within a legitimate sphere and patients intent on using these drugs for illicit purposes, the 
estimated 7 million persons abusing prescriptions drugs annually are simply no match for 
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prescribers and pharmacists. Yet, the line demarcating licit from illicit use of such 
substances proves to be an incredibly thin one. Pharmacists described tolerance and 
withdrawal as properties of any drug a patient may become habituated on. They described 
the effects of suddenly discontinuing any medicinal regimen from blood pressure 
medication to antidepressants. Their claims are bolstered by professional organizations of 
prescribers, such as the American Academy of Pain Medicine. In a press release from 
2003, they state “long term use of opioids results in physical dependence, which is 
different from addiction, but does not usually lead to addiction. Physical dependence 
[emphasis in original] is a normal adaptive state, the expected result of using pain 
medicine (as well as other medications) for a long time.” They define addiction as 
“characterized by impaired control over drug use, compulsive use, and continued use 
despite harm and decreased quality of life” echoing the DSM (2013) definition of 
substance dependence, i.e., a lack of awareness of the drug’s ability to direct behavior 
and influence the body. 
While chronic abuse of illicit drugs are couched in terms such as tolerance and 
withdrawal outlined by the DSM, a special term exists to describe the effects a person 
will experience with suddenly stopping use of their antidepressants, discontinuation 
syndrome. This term emerged following a symposium hosted in 1996 by Eli Lilly and 
Company, the makers of Prozac, as well as an array of other psychiatric medications 
(McHenry 2006). The symposium was held in response to growing criticism that some 
patients experience difficulty in getting off their antidepressants. Eli Lilly had estimated 
“at most a few percent” of individuals would experience the onset of symptoms following 
discontinuation of antidepressants. However, research from Massachusetts General 
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Hospital found this initial estimate to be far too low. Researchers found as many as 
seventy-eight percent of individuals medicated on antidepressants will experience 
symptoms following their discontinuation of the drug (Fava et al. 1997). While some 
antidepressants are more prone to withdrawal symptoms than others (Zoloft and Paxil are 
cited as particularly problematic in this regard; Zajecka, Tracy, Mitchell 1997), these 
rates are significantly higher than the estimates provided by Eli Lilly. Following this 
symposium, however, Eli Lilly established the term “discontinuation syndrome” in an 
effort to distance their drugs from the terminology associated with abuse. Officially, such 
drugs are not classified as having an abuse potential based on animal studies showing rats 
provided free access to the drug do not seek it out. Yet, the commercials filling print and 
video ads urging the public to “ask your doctor about [a drug] to see if it’s right for you” 
along with increasing use of psychiatric and abusable medications attest to the fact that 
individuals do indeed seek these prescriptions out under the urging of pharmaceutical 
companies. 
 Conclusion. As these tensions make clear, the insistence of pharmaceuticals as 
agents of health and well-being and only a patient’s use and perception of the drug’s 
effects separate abuse from dependence more generally, are not perspectives unique to 
pharmacists. Rather, it is a carefully and intentionally constructed dialogue of the 
pharmaceutical industry that couches its products—be they ones more readily associated 
with abuse, such as Vicodin or OxyContin, or psychiatric medications, but not excluding 
other classes of medications—as the definition of care and a healthy relationship between 
patients and the medical establishment, physicians, and pharmacists. Pharmacists actively 
shape these dialogues as they educate patients about medication use and hassle patients 
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they suspect abuse their drugs. As part of this work, they create an assemblage of 
awareness; patient records, a tangible account of their reactions to patients/customers, an 
assemblage of profit, care, biomedicine, a global pharmaceutical market, and the morality 
that emerges to dictate how these disparate pieces coincide.  
As a long history illustrates, boundaries ostensibly separating licit from illicit 
drugs, from pharmacy, sociocultural change, and the pharmaceutical industry are shifting 
and these components are continually being actively shaped to fit changing circumstances. 
Similarly, the global, local, interpersonal, and internal factors all contribute to how drugs 
and their use are conceptualized both in and out of the clinic or pharmacy. The body of 
the addict, as the ideal patient and consumer, becomes an active site for these discourses 
to play out as the persuasive techniques adopted by the pharmaceutical industry and 
medical professionals both attempt to bridge the divides that separate them by couching 
the drugs in the interest of patient health. Similarly, the discipline of pharmacy and the 
assemblage of awareness they compile from a litany of patient interactions, become a site 
where negotiations between the patient, the pharmaceutical industry, and the profession 
of medicine are negotiated. Essential questions—such as: who deserves medications? 
What ethics guide such decision-making? And what to do when the medicines stop 
becoming agents of therapy and become agents of harm?—are asked and answered over 
the pharmacist’s counter. Yet, the ability of the language with which those in the medical 
establishment to adequately answer these questions and slow the trickle of prescriptions 
onto the street for abuse is limited. The pharmaceutical industry has adopted ethos of care 
(e.g., “what is best for the patient?”) and subsumed this dialogue into a language of 
business and profit. It is no small action, as the change to the context with which such 
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pharmaceuticals are delivered and consumed is radically transformed. The addict, while 
the ultimate consumer, is the antithesis of the patient, cured or treated by the therapeutic 
power of pharmaceuticals. Instead, prescription drug abuse constructs addiction and 
business as opposed to patient care. The conflicts that emerge regarding the (il)licit use of 
prescription drugs allows the professional role of pharmacists and the addicted body to 
become sites where micropolitics between dialogues of medicine and care compete with a 
pharmaceutical industry agenda centered on profit-generating work.  
  
	  	  
86	  
References	  Abraham,	  John	  2010	   The	  Sociological	  Concomitants	  of	  the	  Pharmaceutical	  Industry	  and	  Medications.	  In	  Handbook	  of	  Medical	  Sociology.	  Chloe	  E.	  Bird,	  Peter	  Conrad,	  Allen	  M.	  Fremont,	  Stefan	  Timmermans,	  eds.,	  6th	  ed.	  Pp.	  290-­‐308.	  Nashville:	  Vanderbilt	  University	  Press.	  	  Acker,	  Caroline	  Jean	  2002	  	  	  	  	  Creating	  the	  American	  Junkie.	  Baltimore:	  The	  Johns	  Hopkins	  University	  Press.	  Aitken,	  Murray,	  with	  Ernst	  R.	  Berndt	  and	  David	  M.	  Cutler.	  	  2009	   Prescription	  Drug	  Spending	  Trends	  in	  the	  United	  States:	  Looking	  Beyond	  the	  Turning	  Point.	  Health	  Affairs,	  28(1):151-­‐160,	  doi:	  10.1377/hlthaff.28.1.w151	  American	  Academy	  of	  Pain	  Medicine	  2003	   Statement	  on	  Appropriate	  Use	  of	  Opioids.	  Press	  release,	  October	  14:	  http://www.painmed.org/files/opioid-­‐use-­‐statement.pdf,	  accessed	  November	  14,	  2013.	  American	  Association	  of	  Colleges	  of	  Pharmacy	  2013	   Doctor	  of	  Pharmacy	  (PharmD)	  Degree.	  http://www.aacp.org/resources/student/pharmacyforyou/Documents/PharmD.pdf	  American	  Psychiatric	  Association	  
	  	  
87	  
2013	   Diagnostic	  and	  Statistical	  Manual	  of	  Mental	  Disorders,	  5th	  ed.	  Arlington:	  American	  Psychiatric	  Publishing.	  Applbaum,	  Kalman	  2010	   Shadow	  Science:	  Zyprexa,	  Eli	  Lilly	  and	  the	  Globalization	  of	  Pharmaceutical	  Damage	  Control.	  BioSocieties	  5:236-­‐255,	  doi:	  10.1057/biosoc.2010.5.	  Baron,	  Richard	  J.	  2010	  What’s	  Keeping	  Us	  So	  Busy	  in	  Primary	  Care?	  A	  Snapshot	  From	  One	  Practice.	  The	  New	  England	  Journal	  of	  Medicine	  362:	  1632-­‐1636,	  doi10.1056/NEJMon0910793	  Bazazi,	  Alexander	  R.,	  with	  Michael	  Yokell,	  Jeannia	  J.	  Fu,	  Josiah	  D.	  Rich,	  and	  Nikolas	  D.	  Zaller	   2011	   Illicit	  Use	  of	  Buprenorphine/Naloxone	  Among	  Injecting	  and	  Noninjecting	  Opioid	  Users.	  Journal	  of	  Addiction	  Medicine	  5(3):175-­‐180.	  Bell,	  Susan	  E.	  and	  Anne	  E.	  Figert	  2012	   Medicalization	  and	  Pharmaceuticalization	  at	  the	  Intersections:	  Looking	  Backward,	  Sideways,	  and	  Forward.	  Social	  Science	  &	  Medicine	  75:775-­‐783.	  Brodwin,	  Paul	  2010	   The	  Assemblage	  of	  Compliance	  in	  Psychiatric	  Case	  Management.	  Anthropology	  &	  Medicine	  17(2):129-­‐143.	  Brody,	  Howard	  
	  	  
88	  
2007	   Hooked:	  Ethics,	  the	  Medical	  Profession,	  and	  the	  Pharmaceutical	  Industry.	  Lanham:	  Rowman	  &	  Littlefield	  Publishers.	  Brown,	  Daniel	  L.	  2013	   A	  Looming	  Joblessness	  Crisis	  for	  New	  Pharmacy	  Graduates	  and	  the	  Implications	  it	  Holds	  for	  the	  Academy.	  American	  Journal	  of	  Pharmaceutical	  Education	  77(5):90-­‐95.	  Compton,	  Winston	  M.,	  with	  Yonette	  F.	  Thomas,	  Kevin	  P.	  Conway,	  &	  James	  D.	  Colliver	  2005	   Developments	  in	  the	  Epidemiology	  of	  Drug	  Use	  and	  Drug	  Use	  Disorders.	  The	  American	  Journal	  of	  Psychiatry,	  162:1494-­‐1502,	  doi:10.1176/appi.ajp.162.8.1494	  Docter,	  Cary	  2012	   Shorewood	  Police	  Search	  For	  Suspect	  Who	  Robbed	  Pharmacy.	  Fox6	  News,	  January	  2:	  http://fox6now.com/2012/01/02/shorewood-­‐police-­‐search-­‐for-­‐suspect-­‐who-­‐robbed-­‐pharmacy/,	  accessed	  November	  11,	  2013.	  Dugdale,	  David	  C.,	  with	  Ronald	  Epstein	  and	  Steven	  Z.	  Pantilat	  1999	   Time	  and	  the	  Patient-­‐Physician	  Relationship.	  Journal	  of	  General	  Internal	  Medicine	  14(Suppl	  1):S34-­‐S40.	  Fauber,	  John	  2011a	  	  	  	  	  UW	  a	  Force	  in	  Pain	  Drug	  Growth.	  Milwaukee	  Journal-­‐Sentinel,	  April	  2:	  http://www.jsonline.com/watchdog/watchdogreports/119130114.html,	  accessed	  November	  11,	  2013.	  
	  	  
89	  
2011b	  	  	  	  	  UW	  Group	  Ends	  Drug	  Firm	  Funds.	  Milwaukee	  Journal-­‐Sentinel,	  April	  20:	  http://www.jsonline.com/watchdog/watchdogreports/120331689.html,	  accessed	  November	  14,	  2013.	  Fava,	  Maurizio,	  with	  Rosemarie	  Mulroy,	  Jonathan	  Alpert,	  Andrew	  A.	  Nierenberg,	  and	  Jerrold	  F.	  Rosenbaum	  1997	   Emergence	  of	  Adverse	  Events	  Following	  Discontinuation	  of	  Treatment	  with	  Extended-­‐Release	  Venlafaxine.	  The	  American	  Journal	  of	  Psychiatry	  154:1760-­‐1762.	  	  Ford,	  Jason	  A.,	  with	  Fernando	  I.	  Rivera	  2008	   Nonmedical	  Prescription	  Drug	  Use	  among	  Hispanics.	  Journal	  of	  Drug	  Issues,	  38:285-­‐310.	  Freidson,	  Eliot	  1974	   Profession	  of	  Medicine:	  A	  Study	  of	  the	  Sociology	  of	  Applied	  Knowledge.	  New	  York	  City:	  Dodd,	  Mead,	  and	  Company.	  Gallup	  2013	   Honesty/Ethics	  in	  Professions.	  Gallup	  Historical	  Trends.	  http://www.gallup.com/poll/1654/honesty-­‐ethics-­‐professions.aspx,	  accessed	  November	  11,	  2013.	  Geertz,	  Clifford	  1973	   The	  Interpretation	  of	  Culture.	  New	  York	  City:	  Basic	  Books.	  	  Gordon,	  Linda	  
	  	  
90	  
2002	   The	  Moral	  Property	  of	  Women:	  A	  History	  of	  Birth	  Control	  Politics	  in	  America.	  3rd	  ed.	  Urbana:	  University	  of	  Illinois	  Press.	  Gugelmann,	  Halam	  M.	  and	  Jeanmarie	  Perrone	  2011	   Can	  Prescription	  Drug	  Monitoring	  Programs	  Help	  Limit	  Opioid	  Abuse?	  The	  Journal	  of	  the	  American	  Medical	  Association	  306(20):2258-­‐2259,	  doi:10.1001/jama.2011.1712. Gunter,	  Whitney	  D.,	  with	  Steven	  P.	  Kurtz,	  Nicholas	  W.	  Bakken,	  and	  Daniel	  J.	  O’Connell	  2012	   Desisting	  From	  Prescription	  Drug	  Abuse:	  An	  Application	  of	  Growth	  Models	  to	  Rx	  Opioid	  Users.	  Journal	  of	  Drug	  Issues,	  42(1):82-­‐97,	  doi:	  10.1177/0022042612436651	  Gwin	  Mitchell,	  Shannon,	  with	  Sharon	  M.	  Kelly,	  Barry	  S.	  Brown,	  Heather	  Schacht	  Reisinger,	  James	  A.	  Peterson,	  Adrienne	  Ruhf,	  Michael	  H.	  Agar,	  Kevin	  E.	  O’Grady,	  and	  Robert	  P.	  Schwartz	  2009	   Uses	  of	  Diverted	  Methadone	  and	  Buprenorphine	  by	  Opioid-­‐Addicted	  Individuals	  in	  Baltimore,	  Maryland.	  American	  Journal	  of	  Addiction	  18(5):346-­‐355.	  Harrell,	  Zaje	  A.T.,	  with	  Clifford	  L.	  Broman	  2009	   Racial/Ethnic	  Differences	  in	  Correlates	  of	  Prescription	  Drug	  Misuse	  Among	  Young	  Adults.	  Drug	  and	  Alcohol	  Dependence,	  104(3):268-­‐271,	  doi:	  10.1016/j.drugalcdep.2009.05.017	  Healy,	  David	  
	  	  
91	  
2006	   Let	  Them	  Eat	  Prozac:	  The	  Unhealthy	  Relationship	  Between	  the	  Pharmaceutical	  Industry	  and	  Depression.	  New	  York	  City:	  NYU	  Press.	  Huang,	  Boji,	  with	  Deborah	  A.	  Dawson,	  Frederick	  S.	  Stinson,	  Deborah	  S.	  Hasin,	  W.	  June	  Ruan,	  Tulshi	  D.	  Saha,	  Sharon	  M.	  Smith,	  Rise	  B.	  Goldstein,	  and	  Bridget	  F.	  Grant	  2006	   Prevalence,	  Correlates,	  and	  Comorbidity	  of	  Nonmedical	  Prescription	  Drug	  Use	  and	  Drug	  Use	  Disorders	  in	  the	  United	  States:	  Results	  of	  the	  National	  Epidemiological	  Survey	  on	  Alcohol	  and	  Related	  Conditions.	  Journal	  of	  Clinical	  Psychiatry,	  67(7):1062-­‐1073.	  Human	  Rights	  Watch	  2009	  	  	  	  	  Please	  Do	  Not	  Make	  Us	  Suffer	  Anymore:	  Access	  to	  Pain	  Treatment	  as	  a	  Human	  Right.	  Report.	  http://www.hrw.org/node/81079/section/1,	  accessed	  November	  11,	  2013.	  Joranson,	  David	  E.	  and	  Aaron	  M.	  Gilson	  2006	  	  	  	  	  Wanted:	  A	  Public	  Health	  Approach	  to	  Prescription	  Opioid	  Abuse	  and	  Diversion.	  Pharmacoepidemiology	  and	  	  Drug	  Safety	  15(9):632-­‐634,	  doi:	  10.1002/pds.1293	  Joranson,	  David	  E.	  with	  Aaron	  M.	  Gilson	  and	  Martha	  A.	  Maurer	  2005	   Improving	  Opioid	  Availability.	  Indian	  Journal	  of	  Palliative	  Care	  11(2):119-­‐120,	  doi:	  10.4103/0973-­‐1075.19192	  Joranson,	  David	  E.	  with	  M.R.	  Rajagopal	  and	  Aaron	  Gilson	  2002	  	  	  	  	  Improving	  Access	  to	  Opioid	  Analgesics	  for	  Palliative	  Care	  in	  India.	  Journal	  of	  Pain	  and	  Symptom	  Management	  24(2):152-­‐159.	  
	  	  
92	  
Kroutil,	  Larry	  A.,	  with	  David	  L.	  Van	  Brunt,	  Mindy	  A.	  Herman-­‐Stahl,	  David	  C.	  Heller,	  Robert	  M.	  Bray,	  &	  Michael	  A.	  Penne	  2006	   Nonmedical	  Use	  of	  Prescription	  Stimulants	  in	  the	  United	  States.	  Drug	  and	  Alcohol	  Dependence,	  84:135-­‐143,	  doi:	  10.1016/j.drugalcdep.2005.12.011	  Latour,	  Bruno	  2005	   Reassembling	  the	  Social:	  An	  Introduction	  to	  Actor-­‐Network-­‐Theory.	  Oxford:	  Oxford	  University	  Press.	  Maguire,	  T.A.,	  with	  J.C.	  McElnay	  and	  A.	  Drummond	  2001	   A	  Randomized	  Controlled	  Trial	  of	  a	  Smoking	  Cessation	  Intervention	  Based	  in	  Community	  Pharmacies.	  Addiction	  96:325-­‐331.	  Manubay,	  Jeanne	  M.	  with	  Carrie	  Muchow	  and	  Maria	  A.	  Sullivan	  2011	   Prescription	  Drug	  Abuse:	  Epidemiology,	  Regulatory	  Issues,	  Chronic	  Pain	  Management	  with	  Narcotic	  Analgesics.	  Primary	  Care	  38(1):71-­‐vi,	  doi:10.1016/j.pop.2010.11.006	  McCabe,	  Sean	  Esteban	  	  2005	   Correlates	  of	  Nonmedical	  Use	  of	  Prescription	  Benzodiazepine	  Anxiolytics:	  Results	  From	  a	  National	  Survey	  of	  U.S.	  College	  Students.	  Drug	  and	  Alcohol	  Dependence,	  79(1):53-­‐62,	  doi:	  10.1016/j.drugalcdep.2004.12.006	  McCabe,	  Sean	  Esteban,	  with	  Carol	  J.	  Boyd,	  and	  Chrisian	  J.	  Teter	  2006	   Medical	  Use,	  Illicit	  Use,	  and	  Diversion	  of	  Abusable	  Prescription	  Drugs.	  Journal	  of	  American	  College	  Health,	  54(5):269-­‐278.	  
	  	  
93	  
McHenry,	  Leemon	  2006	  	  	  	  	  Ethical	  Issues	  in	  Psychopharmacology.	  Journal	  of	  Medical	  Ethics	  32(7):405-­‐410.	  Meier,	  Barry	  2007	   In	  Guilty	  Plea,	  OxyContin	  Maker	  to	  Pay	  $600	  Million.	  New	  York	  Times,	  May	  10:	  http://www.nytimes.com/2007/05/10/business/11drug-­‐web.html?pagewanted=all&_r=0,	  accessed	  November	  16,	  2013.	  Merline,	  Alicia	  C.,	  with	  Patrick	  M.	  O’Malley,	  John	  E.	  Schulenberg,	  Jerald	  G.	  Bachman,	  and	  Lloyd	  D.	  Johnston	  2004	   Substance	  Use	  Among	  Adults	  35	  Years	  of	  Age:	  Prevalence,	  Adulthood	  Predictors,	  and	  Impact	  of	  Adolescent	  Substance	  Use.	  American	  Journal	  of	  Public	  Health,	  94(1):96-­‐102.	  Meyers,	  Todd	  2013	   The	  Clinic	  and	  Elsewhere:	  Addiction,	  Adolescents,	  and	  the	  Afterlife	  of	  Therapy.	  Seattle:	  University	  of	  Washington	  Press.	  Mol,	  Annemarie	  2008	   The	  Logic	  of	  Care:	  Health	  and	  the	  Problem	  of	  Patient	  Choice.	  New	  York	  City:	  Routledge	  Musto,	  David	  F.	  1984	   Iatrogenic	  Addiction:	  The	  Problem,	  Its	  Definition	  and	  History.	  Journal	  of	  Urban	  Health:	  Bulletin	  of	  the	  New	  York	  Academy	  of	  Medicine,	  61(8):694-­‐705.	  Narcotics	  Anonymous	  
	  	  
94	  
1986	   Why	  Are	  We	  Here?	  Little	  White	  Booklet.	  Van	  Nuys:	  Narcotics	  Anonymous	  World	  Services.	  National	  Institute	  on	  Drug	  Abuse	  	  2011	   Topics	  in	  Brief:	  Prescription	  Drug	  Abuse.	  http://www.drugabuse.gov/publications/topics-­‐in-­‐brief/prescription-­‐drug-­‐abuse,	  accessed	  February	  26,	  2013.	  New	  York	  Magazine	  2009	   A	  History	  of	  Vicodin,	  July	  2:	  http://nymag.com/news/intelligencer/topic/57770/>,	  accessed	  November	  14,	  2013.	  Oldani,	  Michael	  2004	   Thick	  Prescriptions:	  Toward	  and	  Interpretation	  of	  Pharmaceutical	  Sales	  Practices.	  Medical	  Anthropology	  Quarterly	  18(3):325-­‐356.	  Oxford	  English	  Dictionary	  2013	   "addiction,	  n.".	  OED	  Online.	  Oxford	  University	  Press,	  September:	  http://www.oed.com/view/Entry/2179?redirectedFrom=addiction,	  accessed	  November	  16,	  2013.	  Parssinen,	  Terry	  M.	  and	  Karen	  Kerner	  1980	   Development	  of	  the	  Disease	  Model	  of	  Addiction	  in	  Britain,	  1870-­‐1926.	  Medical	  History	  24(3):275-­‐296.	  Paulozzi,	  Leonard	  J.,	  with	  Daniel	  S.	  Budnitz	  and	  Yongli	  Xi.	  
	  	  
95	  
2006	  	  	  	  	  Increasing	  Deaths	  From	  Opioid	  Analgesics	  in	  the	  United	  States.	  Pharmacoepidemiology	  and	  	  Drug	  Safety	  15(9):618-­‐627,	  doi:	  10.1002/pds.1276	  Pletcher,	  Mark	  J.,	  with	  Stefan	  G.	  Kertesz,	  Michael	  A.	  Kohn,	  and	  Ralph	  Gonzales.	  	  2008	   Trends	  in	  Opioid	  Prescribing	  by	  Race/Ethnicity	  for	  Patients	  Seeking	  Care	  in	  US	  Emergency	  Departments.	  Journal	  of	  the	  American	  Medical	  Association.	  299(1):	  70-­‐78,	  doi:10.1001/jama.2007.64.	  Rosaldo,	  Renato	  1980	   Ilongot	  Headhunting,	  1883-­‐1974:	  A	  Study	  in	  Society	  and	  History.	  Stanford:	  Stanford	  University	  Press.	  Simoni-­‐Wastila,	  Linda	  and	  Gail	  Strickler	  2004	   Risk	  Factors	  Associated	  with	  Problem	  Use	  of	  Prescription	  Drugs.	  American	  Journal	  of	  Public	  Health,	  94(2):266-­‐268.	  Sklansky,	  David	  A.	  	  1994	   Cocaine,	  Race,	  and	  Equal	  Protection.	  Stanford	  Law	  Review.	  47:1283-­‐1322.	  http://scholarship.law.berkeley.edu/cgi/viewcontent.cgi?article=2061&context=facpubs&sei-­‐redir=1&referer=http://scholar.google.com/scholar?q=cocaine+crack+race&btnG=&hl=en&as_sdt=0%2C50,	  accessed	  November	  14,	  2013.	  Stimmel,	  Barry	  
	  	  
96	  
1985	   Under-­‐Prescription/Over-­‐Prescription:	  Narcotic	  As	  Metaphor.	  Journal	  of	  Urban	  Health:	  Bulletin	  of	  the	  New	  York	  Academy	  of	  Medicine,	  61(8):742-­‐752.	  Sung,	  Hung-­‐En,	  with	  Linda	  Richter,	  Roger	  Vaughan,	  Patrick	  B.	  Johnson,	  and	  Bridgette	  Thom	  2005	   Nonmedical	  Use	  of	  Prescription	  Opioids	  Among	  Teenagers	  in	  the	  United	  States:	  Trends	  and	  Correlates.	  Journal	  of	  Adolescent	  Health,	  37(1):44-­‐51.	  Swendsen,	  Joel	  et	  al.	  2012	   Use	  and	  Abuse	  of	  Alcohol	  and	  Illicit	  Drugs	  in	  US	  Adolescents.	  Journal	  of	  the	  American	  Medical	  Association	  Psychiatry	  69(4):390-­‐398,	  doi: 10.1001/archgenpsychiatry.2011.1503	  Szasz,	  Thomas	  2007	   Coercion	  as	  Cure:	  A	  Critical	  History	  of	  Psychiatry.	  New	  Brunswick:	  Transaction	  Publishers.	  United	  States	  Department	  of	  Justice	  2011	   State	  Prescription	  Drug	  Monitoring	  Programs:	  Questions	  and	  Answers.	  Drug	  Enforcement	  Agency,	  Office	  of	  Diversion	  Control,	  October:	  http://www.deadiversion.usdoj.gov/faq/rx_monitor.htm.	  	  2013	   Man	  Sentenced	  to	  65	  Years	  Imprisonment	  for	  His	  Involvement	  in	  Robbery	  of	  Pharmacies.	  The	  United	  States	  Attorney’s	  Office,	  Eastern	  District	  of	  Wisconsin.	  Press	  release,	  May	  7:	  
	  	  
97	  
http://www.justice.gov/usao/wie/news/2013/pr20130507_Pharmacy_Robberies_Sentence.html,	  accessed	  November	  11,	  2013.	  United	  States	  Food	  and	  Drug	  Administration	  1970	   Controlled	  Substances	  Act.	  http://www.fda.gov/regulatoryinformation/legislation/ucm148726.htm,	  accessed	  November	  14,	  2013.	  1995	   OxyContin:	  Questions	  and	  Answers.	  http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm207196.htm,	  accessed	  November	  14,	  2013.	  University	  of	  Oxford	  	  2010	   The	  Story	  of	  Penicillin.	  Projects.	  http://www.ox.ac.uk/research/medical_sciences/projects/penicillin.html>,	  accessed	  November	  15,	  2013.	  Ventola,	  C.	  Lee.	  	  2011	   Direct-­‐to-­‐Consumer	  Pharmaceutical	  Advertising:	  Therapeutic	  or	  Toxic?	  Pharmacy	  &	  Therapeutics	  36	  (10):	  669-­‐674.	  	  Williams,	  Trevor	  I.	  1984	   Howard	  Florey:	  Penicillin	  and	  After.	  Oxford:	  Oxford	  University	  Press.	  Wisconsin	  Department	  of	  Justice	  2013	   Heroin:	  A	  Dangerous	  Epidemic.	  Attorney	  General.	  Press	  Release:	  http://www.doj.wi.gov/dci/heroin-­‐awareness/a-­‐dangerous-­‐epidemic,	  accessed	  November	  16,	  2013.	  
	  	  
98	  
Zajecka,	  John,	  with	  Katherine	  A.	  Tracy	  and	  Sunny	  Mitchell	  1997	   Discontinuation	  Symptoms	  After	  Treatment	  with	  Selective	  Serotonin	  Reuptake	  Inhibitors:	  A	  Literature	  Review.	  Journal	  of	  Clinical	  Psychiatry	  58(7):291-­‐297.	  Zillich,	  Alan	  J.,	  with	  Melody	  Ryan,	  Aimee	  Adams,	  Bryan	  Yeager,	  and	  Karen	  Ferris	  2012	   Effectiveness	  of	  a	  Pharmacy-­‐Based	  Smoking-­‐Cessation	  Program	  and	  its	  Impact	  on	  Quality	  of	  Life.	  Pharmacotherapy:	  The	  Journal	  of	  Human	  Pharmacology	  and	  Drug	  Therapy	  22(6):759-­‐765,	  doi:	  10.1592/phco.22.9.759.34073.	  
 
 
